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ABSTRACT 
The human Fyn-related kinase (FRK) is a member of subfamily of Src-related kinases family.  
FRK is 54 kDa non-receptor tyrosine kinase protein composed of 505 amino acids.  FRK consists 
of three functional domains: Src homology 3 (SH3), SH2 and kinase domain, as well as a putative 
tyrosine kinase regulator at the C-terminus.  FRK has a conserved auto-regulatory tyrosine residue 
within its kinase domain.  It has been reported that FRK is repressed in about 30 % of human breast 
cancer samples.  Over-expression of FRK in breast cancer cells of the mammary gland was shown 
to suppress cell growth by interacting, phosphorylating and stabilizing the tumor suppressor 
PTEN, thus inhibiting AKT/PI3K signaling.  Although it has been suggested that FRK is a tumor 
suppressor gene, the effects of activated FRK on cell proliferation, migration and invasion are 
unclear.  Likewise, the signaling pathways regulated by the activation of FRK have not been yet 
fully characterized.  We hypothesize that the activation of FRK is essential for the regulation of its 
cellular functions.  Mutation of the C-terminal auto-regulatory tyrosine 497 to phenylalanine 
(FRK-Y497F) resulted in the constitutive activation of FRK.  We generated stable cell lines 
expressing either the FRK wild type (FRK-WT) or FRK-Y497F from triple negative breast cancer 
MDA-MB-231 cells.  The introduction of FRK-Y497F in MDA-MB-231 cells significantly 
suppressed their proliferation, migration, invasiveness and colony formation as compared to cells 
that expressed the FRK-WT gene.  Over-expression of either FRK-WT or FRK-Y497F in MDA-
MB-231 cells inhibited the phosphorylation of AKT, STAT3, JNK and P38 MAPK as compared 
to either the MDA-MB-231 parental cells or those that were transfected with the empty vector.  
Our results suggested that FRK represses cell proliferation, migration, invasiveness and colony 
formation at least in part by the inhibiting the activation of AKT/PI3K, JAK-STAT and MAPK 
signaling pathways. 
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1. OVERVIEW 
Breast cancer is a global public health issue with over 1.5 million predicted diagnoses in 
women worldwide (Ginsburg and Love 2011).  Breast cancer accounts for up to 23% of all 
cancers in women, and it causes 500,000 deaths worldwide each year (Ginsburg and Love 
2011).   
One of current breast cancer molecular classifications is based on gene expression 
profiles of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) (Rakha et al., 2010).  Based on the status of these 
receptors, breast cancer can be classified into 4 major molecular subtypes: Luminal A, 
Luminal B, triple negative and HER2 type (Perou et al., 2000; Sorlie et al., 2001; Prat and 
Perou 2011).  HER2 type breast cancers are characterized by overexpression of the HER2 
receptor and tend to be poorly differentiated and high-grade (Brenton et al., 2005).  Triple-
negative type, lacking ER, PR or HER2 expression, is a relatively more malignant form of 
breast cancer with poor prognosis.  5-10% cancer patients have been diagnosed with triple-
negative type (Carey et al., 2010).  Since triple-negative breast cancers lack the three 
receptors (ER, PR and HER2), common clinical drugs cannot be used towards treating such 
breast cancers (Carey et al., 2010).  Both luminal A and B cancers express ER/PR genes.  
Luminal B also contains HER2 and appears to be more aggressive (Perou et al., 2000; 
Sorlie et al., 2001; Prat and Perou 2011).  Breast cancer cell lines also exhibit heterogeneity 
in the expression of several other cellular genes (Neve et al., 2006).  Tumor heterogeneity 
has complicated patient response to therapeutic strategies.  Breast cancer heterogeneity in 
the context of genomic profile (gene mutation, gain or loss of gene copy number), 
expression signature of prognostic markers such as HER2 and ER, all contribute to the 
complexity of therapeutic intervention.  The various interventions used in the treatment of 
breast cancer include surgery, radiation, chemotherapy and immunotherapy.  Often, 
surgery is more effectively used in combination with chemotherapy and radiation.  
However, there are several limitations associated with the use of chemotherapeutic drugs, 
such as target inaccuracy.  The inaccuracy can be compensated by the use of combination 
therapy by either using hormone blocking therapy or the use of monoclonal antibodies 
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specific to antigens overexpressed in cancerous cells such as tyrosine kinase inhibitors that 
target breast cancer cells overexpressing HER2/neu (Roskoski 2014).  Mutation or 
overexpression of tyrosine kinases are known to contribute to the development of tumors 
(Morel et al., 2014).  
Protein kinases are classified into two sub-families based on their substrate 
specificity: serine/threonine kinases and tyrosine kinases (Hanks et al., 1988).  Protein 
tyrosine kinases (PTKs) catalyze the transfer of a phosphate group, derived from ATP, to 
specific tyrosine residues (Condorelli et al., 2011).  PTKs play a vital role in intracellular 
and extracellular signal transduction, and the regulation of cellular proliferation (Morel et 
al., 2014).  PTKs can be further sub-classified into two groups as receptor tyrosine kinases 
(RTKs) and non-receptor tyrosine kinases (NRTKs) based on their cellular locations 
(Chandrasekharan et al., 2002).   
Receptor tyrosine kinases (RTKs) consist of three key domains, a hydrophobic 
trans-membrane domain which is embedded in the cellular lipid membrane, an 
extracellular domain that is responsible for activating intracellular kinases via specific 
ligand binding, and a cytoplasmic domain which contains the recruitment sites for the 
downstream substrates  (Blume-Jensen and Hunter 2001).  Unlike RTKs, NRTKs mainly 
have a cytoplasmic localization and their downstream regulation is achieved by activating 
the tyrosine in the protein by transferring a phosphate group from a phosphate donor.  The 
human genome encodes nearly 32 NRTKs.  Src family kinases (SFKs) and and Fyn-related 
kinase (FRK) are examples of NRTKs (Robinson et al., 2000).  The hyperactivation of 
certain PTKs has been linked to the tumorigenesis of breast cancer (Nunes-Xavier et al., 
2013).  For example, the overexpression of cholecystokinin tetrapeptide (CCK-4/PTK7) 
has been reported in different types of cancers including lung, colon and breast cancer 
(Mossie et al., 1995; Speers et al., 2009; Na et al., 2012).  Two PTK family proteins: the 
HER2 and SFKs have been shown to highly correlate with the development of breast 
cancer (Nunes-Xavier et al., 2013). 
c-Src is the prototypical member of the Src family kinases.  Due to the sequence 
homology and structural similarities, SFKs have been separated into eight family members, 
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Src, Fyn, Yes, Blk, c-Fgr, Lyn, Lck and Hck (Figure 2.5) (Abram and Courtneidge 2000).  
v-Src was one of the first well-studied viral oncogenes (Smart et al., 1981), while its 
ortholog, c-Src, was reported to exhibit protooncogenic properties, as studied in normal 
cells (Oppermann et al., 1979).  The presence of N-terminal myristoylated glycine residues 
in SFKs enable interaction with cellular membranes (Okada 2012).   
The dephosphorylation of C-terminal tyrosine 530 relieves binding interaction with 
the Src homology 2 (SH2) domain.  This results in a conformational change at the kinase 
domain that induces a hydrogen bond between glutamate 310 existing in C-helix and 
lysine 295 (Okada 2012).  As a result, tyrosine 416 which is located in the activation loop 
is auto-phosphorylated.  c-Src is known to exhibit oncogenic properties (Oppermann et al., 
1979).  Elevated expression and activation of c-Src has been commonly found in a variety 
of cancers, including human breast cancer (Verbeek et al., 1996).  For instance, the activity 
of c-Src has been found to be elevated in human brain and skin tumors (Homsi et al., 2007; 
Ahluwalia et al., 2010).  In addition, elevated expression of c-Src has been reported in 
certain malignancies such as ovarian cancer (Wang et al., 2014).  Src activation has been 
also reported to associate with prostate cancer metastases (Vlaeminck-Guillem et al., 
2014). 
Unlike c-Src, FRK appears to function as a tumor suppressor (reviewed by (Serfas 
and Tyner 2003; Brauer and Tyner 2009)).  For instance, in a recent paper the mRNA and 
protein levels of FRK were found to inversely correlate with the grade of human glioma 
tumors.  While normal brain tissue exhibited elevated FRK levels, high grade glioma 
tissues exhibited significantly reduced levels of FRK, suggesting a potential tumor 
suppressive role in human glioblastomas (Zhou et al., 2012). 
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2. REVIEW OF LITERATURE 
2.1 Cell signaling pathways in cancer 
In cell signaling, receptors usually are activated by the ligand binding.  Receptor activation 
leads to the transmission of intracellular signals which eventually elicits a cellular response.  
This entire process of cell response driven by signal transmission constitutes a cell signal 
transduction pathway (Dinasarapu et al., 2011).  A series of signaling pathways exist within 
cells, comprising several proteins that participate in signal transmission.  These pathways 
are organized in complex networks with distinct pathways tending to cross-talk with other 
pathways within the cell.  Before providing background information on Fyn-related kinase 
(FRK), which is the focus of the thesis, signaling pathways relevant to the cellular 
properties FRK and key signaling intermediates will be introduced briefly in the following 
sections. 
 
2.1.1 The Mitogen-Activated Protein Kinase signaling pathway 
The Mitogen-Activated Protein (MAP) kinases, protein serine/threonine kinases, are one 
of the major components of the signal transduction pathways regulating cellular processes 
in the nucleus, including cell proliferation, apoptosis, differentiation and activities of 
intracellular enzymes (Gao et al., 2014).  These kinases contain two domains, a highly 
helical C-terminal domain and an N-terminal domain.  The former is composed of four -
strands which contain several catalysis-related residues and the latter is mainly constructed 
of -sheets and 2 helices (C and L16) (Turjanski et al., 2007). 
The activation of MAP kinases (MAPKs) is modulated by three-kinase 
phosphorylation cascades (Figure 2.1).  Mitogen-Activated Protein kinase kinases 
(MAPKKs) are responsible for phosphorylating the downstream target MAPKs, and its 
own activation relies on upstream protein kinases, Mitogen-Activated Protein kinase 
kinase kinases (MAPKKKs) (Pimienta and Pascual 2007).  The phosphorylation of 
tyrosine and threonine are both required for activating MAPKs by MAPKKs.  Moreover, 
the threonine phosphorylation is crucial for activation of tyrosine-phosphorylated proteins, 
thereby fully activating MAPKKs (Pimienta and Pascual 2007).  Likewise, MAPKKKs 
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activate MAPKKs via a similar process, by the phosphorylation of either a tyrosine or 
threonine residue located in the activation loop (Alessi et al., 1994; Zheng and Guan 1994).  
Consequently, activated MAPKs translocate from cytoplasm to the nucleus where they 
regulate gene transcription (Gonzalez et al., 1993).  In the nucleus, MAPKs interact with 
targeted transcription factors and initiate gene transcription (Pimienta and Pascual 2007). 
 
 
Figure 2.1.  Simplified MAPK and JAK-STAT signaling pathway.  Mitogenic-
activated protein kinase (MAPK) regulates several cellular processes including cell 
proliferation, cell differentiation, cell migration and cell survival through the modulation 
of several signaling pathways.  MAPKKK are activated by cell surface receptor stimulation 
by various growth factors.  MAPKKK activates MAPKK, which in turn activates MAPK.  
JAKs (Janus kinase) and STATs (Signal Transducer and Activator of Transcription) are 
critical components of many cytokine receptor systems, regulating cell proliferation, cell 
differentiation and pathogen resistance.  JAK2 receptor stimulation results in the 
phosphorylation of STAT3 at tyrosine 705, which induces dimerization, followed by 
nuclear translocation and activation of several target genes including those that modulate 
cell growth, differentiation and pathogen resistance (Turjanski et al., 2007).  Figure is 
modified from http://www.cellsignal.com/contents/science-cst-pathways/map-kinase-
signaling-resources/science-pathways-mapk?Ntt=MAPK&fromPage=keywords. 
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According to sequence similarity, MAPKs can be categorized into 6 groups, 
including the extracellular signal-regulated protein kinases (ERK1 and ERK2), c-Jun N-
terminal kinases (JNK1, JNK2, JNK3), p38s (p38, p38, p38, p38),ERK3s (ERK3, 
p97 MAPK, ERK4), ERK5 (ERK5), and ERK7 (ERK7, ERK8) (Schaeffer and Weber 
1999), which will be discussed in detail in the following sections. 
 
2.1.1.1 The ERK 1/2 pathway 
ERK1 (extracellular signal-regulated kinase 1) and ERK2 are two isoforms, proteins of 42 
and 44 kDa (also known as p42MAPK and p44MAPK), respectively (Rossomando et al., 1989).  
The activation loop of ERK contains a TEY motif (Thr-Glu-Tyr), in which theronine and 
tyrosine are essential for activating the kinase (Payne et al., 1991).  MEK1 and MEK2 are 
capable of fully activating ERK1 and ERK2 (Zheng and Guan 1993; Robinson et al., 1996). 
The mammalian ERK 1/2 pathway has several important biological functions, 
including cell survival, proliferation and development (Zhang and Dong 2007).  The three-
kinase module of MAPKs regulation can also be applied to describe the ERK 1/2 pathway.  
In epidermal growth factor receptor (EGFR) signaling, for example, interaction of its 
ligand epidermal growth factor (EGF) with EGFR results in receptor dimerization which 
consequently activates EGFR itself.  Once the receptor is activated, tyrosine 
autophosphorylation creates tyrosine-specific binding sites which are crucial for 
phosphorylating a series of downstream substrates, including growth factor receptor-bound 
protein 2 (Grb2) (Ullrich and Schlessinger 1990; Schlessinger and Ullrich 1992; Buday 
and Downward 1993).  Grb2 subsequently binds to SOS (Son of  Sevenless, drosophila 
homolog 1), and induces the replacement of GDP (Guanine diphosphate) bound to Ras 
with GTP.  Therefore, activated Ras can propogate the signaling to Raf1, MEK 1/2 and 
ERK 1/2, sequentially (Ullrich and Schlessinger 1990; Pearson et al., 2001).  MEK 1/2, 
then phosphorylates and activates ERK 1/2 (Prowse et al., 2000) (Figure 2.1).  The 
activation of ERK 1/2 triggers its nuclear translocation, and subsequent binding to certain 
transcription factors, thus regulating gene expression (Turjanski et al., 2007).  The activator 
protein-1 (AP-1) is a well-characterized example to illustrate the regulatory function of 
ERK 1/2 at the transcriptional and post-translational levels.  The AP-1 complex, which is 
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required for c-myc expression, is formed by the Jun family of transcription factors (c-Jun, 
JunB and JunD) heterodimerizing with the Fos family proteins (c-Fos, FosB, Fra1 and Fra2) 
(Angel and Karin 1991).  In addition, c-fos transcription is modulated by the binding of 
ternary complex factor (TCF, also known as Elk-1) to c-fos promoter region upon the 
activation of ERK 1/2 (Whitmarsh et al., 1995) (Figure 2.2). 
 
2.1.1.2 c-Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK) 
pathway 
JNKs (c-Jun N-terminal kinases), also known as stress-activated protein kinases, have three 
identified coding genes, including JNK1, JNK2 and JNK3 (Cargnello and Roux 2011).  
Like other MAPKs, the activation loop of JNK contains a specific Thr-Pro-Tyr motif 
(Cargnello and Roux 2011).  JNK was discovered by its capability of serine-
phosphorylating the transactivating domain, which is located at the N-terminus of c-Jun 
(Turjanski et al., 2007). 
 JNK regulates several biological processes, including apoptosis, differentiation and 
proliferation (Briata et al., 2005).  Like MAPK signaling pathway, JNK initiates its kinase 
cascade by receiving extracellular stimuli, although the mechanism of the activation has 
not been fully investigated as that in ERK (Figure 2.2).  Similar to the ERK 1/2 pathway, 
which is regulated by Ras, the activity of JNK was found to be regulated by two of the Rho 
family of GTPases (Rac1 and Cdc42) through switching on an independent pathway 
(Turjanski et al., 2007).  Substrates of GTPases involved in the JNK pathway include 
members of MAPKKK family (MEKK1-4), the apoptosis signal-regulating kinase (ASK) 
family (ASK1 and ASK2), the mixed-lineage protein kinase family (Zhu et al., 2014), TPL2, 
and TGF--activated kinase 1 (TAK1) (Coffey 2014).  In addition, two more kinases, 
MEK4 and MEK7, have been shown to regulate the function of JNK (Hsiao and Stapleton 
2004).  MEK4 activates JNK via tyrosine-phosphorylation at Tyrosine 185, whereas MEK7 
prefers threonine phosohorylation at Threonine 183, although they both can activate JNK 
via dual phosphorylation (Hsiao and Stapleton 2004). 
JNK and its upstream activators, MEK7 and MLK3, are recruited to the scaffolding 
protein JNK interacting protein 1 (JIP1), forming a complex which subsequently facilitates 
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the phosphorylation of JNKs induced by Rac (Turjanski et al., 2007).  Thus, the activated 
JNKs translocate from the cytoplasm to the nucleus to control the expression of several 
genes including the c-jun gene.   
 
 
Figure 2.2.  Spatiotemporal model of MAPK cascade.  Stimulated by mitogens, certain 
growth factor receptors are phosphorylated and activated, thereby inducing the activation 
of GTPase of the Rho and Ras family via the guanine-nucleotide exchange factors (GEF).  
Rac and Ras then activate the corresponding downsteam kinase cascades.  In one hand, Ras 
activates the Raf/MEK/ERK cascade.  In the other hand, Rac activates another independent 
JNK interacting protein 1 (JIP1)-mediated signaling pathway.  JNK is activated by forming 
a complex with its activators, MKK7 and MLK3, and the scaffolding protein JIP1.  The 
phosphorylated JNK translocates to the nucleus to modulate the target gene expression.  
Activated JNK, ERK participate in the phosphorylation of activating transcription factor 2 
(ATF2), Jun and T-cell factor (TCF) which are required for c-Jun and c-Fos gene 
expression.  Figure is adapted from (Turjanski et al., 2007). 
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2.1.1.3 The p38 pathway 
The p38 family has four members, including p38, p38, p38 and p38.  p38 the best 
known member in the family, has been identified as a tyrosine phosphoprotein in response 
to inflammatory cytokines (O'Callaghan et al., 2014).  Three other isoforms have also been 
identified, including p38(p38-2), p38(ERK6 or SAPK3), and p38 (SAPK4) (Jiang et 
al., 1996; Lechner et al., 1996; Li et al., 1996; Goedert et al., 1997; Jiang et al., 1997; 
Kumar et al., 1997; Stein et al., 1997).  All four p38 family members share a similar 
structure, which contains a dual phosphorylation motif (Thr-Gly-Tyr) located in the 
activation loop (Cargnello and Roux 2011).  Therefore, these members are similar to one 
another in function to a degree.  For example, p38and p38, not only have the similar 
downstream targets (MAPKAPK2 and ATF-2), but are both sensitive to pyridinyl 
imidazole which acts as a p38 kinase activity inhibitor competing with ATP (Hu et al., 
1999; Zarubin and Han 2005).  However, these isoforms are also distinct in certain 
properties.  Unlike p38and p38, the other two isoforms p38and p38, are resistant to 
pyridinyl imidazole (p38 MAPK inhibitor) and may even inhibit the activity of AP-1 
(Goedert et al., 1997; Kumar et al., 1997; Pramanik et al., 2003).  
 It has been proposed that the p38 family proteins are stimulated by a variety of 
factors, including exposure of cells to GPCRs, cytokines, osmotic and heat shock, cell 
stress signals (Conrad et al., 1999) and hormones (Turjanski et al., 2007).  p38 has also 
been reported to respond to inflammation via the modulation of expression of Interleukin 
1 (IL-1, cyclooxygenase 2 (COX-2), Interleukin 6 (IL-6) and tumor necrosis factor- 
(TNF-) (reviewed in (Zarubin and Han 2005)).  MEK3 and MEK6 have been shown to 
contribute to the activation of p38s by phosphorylating the four isoforms (Carriere et al., 
2008).  However, a preference of phosphorylation exists as MEK3 tends to phosphorylate 
p38and p38 while MEK6 prefers to initially activate p38and p38 isoforms 
(O'Callaghan et al., 2014).  DNA-damage induced cell apoptosis, another important 
biological process, is also particularly regulated by p38s via serine-phosphorylation of 
tumor suppressor protein p53, inducing the chemosensitivity of cancer cells (Sanchez-
Prieto et al., 2000).   
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2.1.1.4 Other MAPK pathways 
There are other kinases which are homologous to the MAPKs family, including ERK3 
isoforms, ERK5, ERK7, NLK and MOK (Cargnello and Roux 2011).  The activity of 
ERK5 is modulated by a series of stimulations, such as cell-stressing and proliferation-
related agents.  The activation pathways of ERK5 also depend on the cell types and 
extracellular stimuli (Nithianandarajah-Jones et al., 2012).  The proliferation-related 
ligands include EGF, serum, phorbol easer, lysophosphatidic acid (LPA) and nerve growth 
factor (NGF) (Kato et al., 1997; Kato et al., 1998; Kamakura et al., 1999).  The Ras-
independent activation pathway has been indicated to be responsible for these proliferative 
stimuli in certain cell lines (Kato et al., 1997; Kato et al., 1998).  On the other hand, the 
stressful conditions could be created by UV irradiation, ischemia, sorbitol, vascular shear 
stress and H2O2 (Abe et al., 1996; Kato et al., 1998; Kamakura et al., 1999; Takeishi et al., 
1999; Yan et al., 1999), and stress-induced activation prefers the Src-dependent pathway 
(Abe et al., 1997).  The signaling pathways of most members have not been fully 
investigated.  For instance, ERK3 isoform, ERK3,  has been found localized to the 
nucleus, but only a few studies reveal its regulation pathways (Cheng et al., 1996).  ERK3 
has been described to be activated via serine-phosphorylation at Ser 189 by an upstream 
regulator which was not able to stimulate other MAPKs; however, the molecular 
mechanism still remains unknown (Cheng et al., 1996).   
 
2.1.2 The PI3K-AKT/PKB signaling pathway 
The phosphoinositide 3-kinase (PI3K) is an intracellular lipid heterodimeric enzyme 
composed of a catalytic and a regulatory subunit.  PI3K family contains eight isoforms 
which are classified into three different categories (I, II and III) based on sequence 
homology and substrate preference (Cantley 2002; Vanhaesebroeck et al., 2010; 
Vanhaesebroeck et al., 2010).  Class I,  the most studied subfamily among the three classes, 
can be further divided into IA and IB (Zhao and Vogt 2008).  The former, consisting of 
p85 regulatory subunit and p110 catalytic subunit, is activated by RTKs (Zhao and Vogt 
2008).  The latter contains p101 regulatory subunit and  catalytic subunit (Zhao and 
Vogt 2008) and is stimulated by G-protein-coupled receptors (GPCRs) (Yap et al., 2008).  
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Three isoforms were found in the p110 subunit (,  and ) and five isoforms in the p85 
subunit (p85, p55, p50, p85 and p85) (Okkenhaug and Vanhaesebroeck 2001; Ward 
et al., 2011).  There are SH2 and SH3 domains in the p85 subunit, and the SH2 domain 
tends to bind phosphorylated tyrosine usually within a (Y-X-X-M) motif (Songyang et al., 
1993; Yoakim et al., 1994).  The class I is responsible for the formation of 
phosphatidylinositol 3-phosphate (PI(3)P), phosphatidylinositol (3,4)-biosphosphate 
(PI(3,4)P2) and phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3) (Okkenhaug 2013) 
which participates in numerous intracellular processes including cell proliferation, survival, 
reorganization of cytoskeleton, membrane transition, adhesion, mobility, angiogenesis and 
insulin action (Engelman 2009).   
The conversion of PI(4,5)P2 to PI(3,4,5)P3, the most important product in vivo 
(Cortot et al., 2006), is achieved via the phosphorylation by PI3K on the membrane.  
PI(3,4,5)P3 induces the recruitment of the pleckstrin homology (PH) domain-containing 
proteins to the cell membrane.  Thus, the signal can be transduced upon the activation of 
PI3K (Engelman et al., 2006).  
AKT, also known as protein kinase B, a serine/threonine kinase, was first identified 
as an oncogene which is transduced by leukemia-inducing AKT-8 in mice (Staal 1987).  
There are three cancer-related isoforms in the AKT family: AKT1, AKT2 and AKT3 
(Murthy et al., 2000; Koseoglu et al., 2007).  AKT has been reported to be activated by 
various stimuli including EGFR and insulin-like growth factor-1 receptor (IGF-1R), as well 
as GPCRs (Hennessy et al., 2005).  AKT is an important central node in the PI3K signaling 
pathway, and the N-terminal PIP3-binding PH domain of AKT is required for the anchorage 
of the plasma membrane (Andjelkovic et al., 1997; Frech et al., 1997).  This results in a 
consequent conformational change of AKT which leads to the threonine-phosphorylation 
of its own activation loop by another phosphoinositide-binding protein, phosphoinositide-
dependent kinase 1 (PDK1) at Thr308 (Alessi et al., 1997; Engelman et al., 2006).  In order 
to be fully activated, the phosphorylation at C-terminal serine 473 of AKT is also required 
by the mammalian target of rapamycin complex 2 (mTORC2) (Sarbassov et al., 2004; 
Sarbassov et al., 2005).  Similar to MAPKs, fully active AKT then translocates to the 
nucleus to exert its gene regulatory function, involved in cell proliferation, survival, 
metabolism and glucose homeostasis (Manning and Cantley 2007; Yap et al., 2008). 
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There are several AKT-regulated processes (Yap et al., 2008).  The anti-apoptotic 
property of the AKT signal pathway has been well characterized.  AKT phosphorylates 
and inhibits the activation of potential apoptosis-inducing proteins, including MDM2, 
BAD and members of the Forkhead family (del Peso et al., 1997; Brunet et al., 1999; Mayo 
and Donner 2001).  It has also been shown that AKT inhibits the activation of p27 (Fujita 
et al., 2002), Myc and cyclin D1, which are activated by glycogen synthase kinase 3 
(GSK3), thereby promoting cell growth (Vivanco and Sawyers 2002).  AKT also 
participates in metabolism, proliferation and angiogenesis regulation.  For instance, the 
inactivation of GSK3 via a phosphorylation by AKT (Cross et al., 1995) blocks AS160 
and triggers the glucose transporter Glut4 translocation to the cell membrane (Sano et al., 
2003), while the inactivation of FOXO induces the inhibition of glucose-6-phosphatase 
and phosphoenolpyruvate carboxykinase (Burgering 2008). 
In addition, AKT also has been shown to act at transcriptional level via modulating 
the mTORC1 complex (Figure 2.3), consisting of mTOR and some interactors (Guertin 
and Sabatini 2007).  The regulation of mTORC1 by AKT can be illustrated by two distinct 
pathways.  One is through the phosphorylation and inactivation of GTPase-activating 
protein (GAP) TSC2 (Dan et al., 2002), forming a complex with TSC1.  In the other 
pathway, PRAS40 (proline-rich AKT substrate of 40 KDa) down-regulates the mTORC1 
by competing with the GTPase Rheb (Ras-homolog enriched in brain) (Kovacina et al., 
2003; Sancak et al., 2007). 
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Figure 2.3.  PI3K-AKT-mTORC1 pathway.  The PI3K-AKT-mTORC1 signaling 
cascade is inhibited by the tumor suppressor PTEN.  Figure is adapted from (Carracedo 
and Pandolfi 2008). 
 
2.1.3 The JAK-STAT signaling pathway 
Signal transducer and activator of transcription (STATs) have seven identified members in 
mammals that include STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 
(Haricharan and Li 2014).  STATs can directly interact with RTKs and NRTKs via 
phosphorylation (Aaronson and Horvath 2002).   
The JAK-STAT system is responsible for transducing extracellular signal through 
the cell membrane into the cell nucleus, where the gene transcriptional activity is regulated 
via the binding of STATs and transcription factors.  The JAK-STAT system consists of 
three components: a receptor, Janus kinase (JAK) and STAT proteins, all of which play 
key roles in the signal transduction cascades.  There are four members in the JAK family: 
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JAK1, JAK2, JAK3, and TYK2 (O'Shea et al., 2013).  JAKs have tyrosine kinase activity, 
and are triggered by binding to cytokine receptors.  Activated JAKs are capable of 
phosphorylating cytokine receptors and creating the recruitment sites for STATs which 
possess a phospho-tyrosine-binding SH2 domain (Qi and Yang 2014).  The STATs are 
tyrosine-phosphorylated by JAKs after being recruited to the receptors (Qi and Yang 2014).  
Phosphorylated STATs dimerize and translocate into the nucleus, where they initiate the 
transcription of genes involved in the regulation of cell proliferation, migration and 
differentiation (Qi and Yang 2014). 
There are three different signaling pathways in JAK-STAT depending on different 
extracellular stimuli, including type I IFN, type II IFN and interleukin 6 (IL-6).  STAT3 
regulation of gene transcription in response to IL-6 stimuli results in the modulation of 
diverse cellular and physiological process including cell proliferation, inflammatory 
responses and the development of early embryos (reviewed in (Akira 2000; Hirano et al., 
2000)).  Being a member of the STAT family of transcription factors, STAT3 consists of a 
DNA binding domain, an SH2 domain which is required for its homo- or hetero-
dimerization and a regulatory tyrosine 705 at the C-terminus controlled through 
phosphorylation by a tyrosine kinase (Qi and Yang 2014).  Studies have indicated that the 
activation of STAT3 correlates with many types of cancer (Bollrath et al., 2009; 
Grivennikov et al., 2009).  The tyrosine phosphorylation sites in intracellular domains of 
cytokine receptors and the binding of JAK1 and JAK2 proteins to receptors are two factors 
required for recruitment of STAT3 by providing a STAT3 phosphorylation docking site.  
The ensuing dimerization of phosphorylated STAT3, triggers its subsequent nuclear 
localization (Figure 2.4).  STAT3 is responsible for initiating the target gene expression 
by specific binding to promoters, which contain a sis-inducible element (SIE) (also known 
as GAS element).  STAT3 can be activated not only by cytokine, but also triggered by 
other routes, such as growth factors (EGF and PDGF) via specific tyrosine-phosphorylation 
(reviewed in (Aaronson and Horvath 2002)). 
Activated STAT3 has also been reported to initiate the transcription of several 
genes involved in breast cancer development and progression, such as cyclin D1, cMyc, 
Bcl-xL, Survivin, VEG-f and Klf-8 (reviewed by (Haricharan and Li 2014)). 
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Figure 2.4.  STAT3-mediated JAK-STAT signaling pathway.  Upon IL-6 stimulation, 
JAK1 and JAK2 are phosphorylated and activated, creating a docking site for STAT3 and 
inducing its phosphorylation.  Phosphorylated STAT3 dimerize and translocate to the 
nucleus and subsequently initiate the gene expression by binding to certain transcriptional 
promoters. 
 
JAK-STAT signaling pathway has been proposed to be repressed at multiple levels 
which includes the inactivation of JAK1, JAK2 and STAT3 (Shuai 2000; Shuai and Liu 
2003).  Suppressors of Cytokine Signaling (SOCS) has been confirmed as an inhibitor of 
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cytokine signaling cascades through binding to JAKs and inhibiting its kinase activity 
(Krebs and Hilton 2001).  JAK-STAT pathway can also be down-regulated by the protein 
tyrosine phosphatases (PTPase), keeping STATs and JAKs inactive.  A typical example 
for this type of negative regulation involves TC45, a nuclear isoform of T-cell PTP (TC-
PTP) which has been shown to dephosphorylate STAT1 both in vitro and in vivo, thereby 
impacting signaling via the STAT-JAK pathway (ten Hoeve et al., 2002).  Protein 
Inhibitors of Activated STAT (PIAS), another protein reported to regulate the JAK-STAT 
pathway, has been shown to interfere with STATs dimerization and inhibit the DNA-
binding activity of the transcription factors (Shuai 2006).  In addition, PIASs have been 
shown to suppress the transcription via recruitment of other co-repressors (Liu et al., 2001; 
Arora et al., 2003).  
 
2.2 Human FRK and its murine orthologs  
2.2.1 Human FRK 
The Human Fyn-related Kinase (FRK, also known as Rak or protein tyrosine kinase 5, 
PTK5) is a non-receptor tyrosine kinase, composed of 505 amino acids with a molecular 
weight of 54 kDa (Lee et al., 1994).  As a distant member of Src family, FRK shares 51% 
similarity with the primary sequence of Fyn (Cance et al., 1994).  The FRK protein has so 
far been detected in the human hepatoma cell line Hep3B (Lee et al., 1994), human 
melanocytes (Martinez et al., 1987), human B-cell lymphoma cell line BL979, colon 
cancer cell line LS 180, breast cancer cell lines BT20 and 600 PEI and primary human 
breast cancer cells (Cance et al., 1994).  The expression of FRK also showed a tissue-
specific pattern in normal cells.  Both mRNA levels and expression levels of protein were 
shown to be predominantly in human epithelial tissues derived from the liver and kidneys 
(Cance et al., 1994).  A recent study also reported high mRNA levels of FRK in normal 
lung tissue (Chen et al., 2013).  Moreover, the expression level of FRK protein has also 
been observed in human normal breast epithelial tissues (Berclaz et al., 2000).  However, 
its mRNA expression was absent in cells derived from the mesenchymal tissue such as 
skeletal muscle (Cance et al., 1994).   
FRK belongs to a distinct family of NRTKs, known as the FRK family, that 
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includes protein tyrosine kinase 6 (PTK6, also called BRK) and SRMS (Src-related kinase 
lacking C-terminal regulatory tyrosine and N-terminal myristoylation sites) (Serfas and 
Tyner 2003).  The FRK family kinases share a conserved gene structure that is distinct 
from that of the SFKs.  From the protein level, the FRK family lacks palmitoylation and 
myristoylation signals which are responsible for membrane anchorage of the Src family.   
Like SFKs, FRK consists of 3 functional domains, the SH3 domain, the SH2 
domain and a kinase domain.  The carboxy terminal region of FRK possesses an 
autoregulatory tyrosine 497, analogous to the Y530 of human c-Src.  The kinase activity 
of FRK is inhibited when the regulatory tyrosine is phosphorylated (Pendergast 1996; 
Parsons and Parsons 2004).  FRK has a conserved auto-regulatory tyrosine residue Y387 
within its kinase domain.  Overall, FRK displays a similar architecture to Src and has 30–
40% sequence identity with SFKs (Serfas and Tyner 2003).  The SH2 domain binds 
specifically to peptide sequences that contain a phosphorylated tyrosine (pTyr), while the 
SH3 domain tends to bind polyproline-containing ligands more commonly displaying a 
PXXP motif (Kaneko et al., 2011).  
In SFKs, the inactive conformation of the enzyme is stabilized by intermolecular 
interactions between the C-terminal phosphotyrosine (pY530 in human Src) and the SH2 
domain, and between proline residues in the SH2-kinase linker and the SH3 domain 
(Parsons and Parsons 2004). Mutation of the C-terminal tyrosine in SFKs, as well as in 
PTK6-Y447F mutant and murine FRK-Y504F which is analogous to Y497 in the human 
sequence (Figure 2.5) have been shown to increase the catalytic activity of the enzymes 
(Oberg-Welsh et al., 1998; Derry et al., 2000; Roskoski 2004). 
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Figure 2.5.  A schematic representation of the BRK, c-Src, FRK and its murine 
ortholog Bsk/Iyk protein structures showing the critical regulatory and functional 
elements.  In the Src inactivation form, the SH2 domain binds to the C-terminal tyrosine 
527 (FRK Y497, BSK Y504; BRK Y447), the SH2-catalytic linker which contains a key 
residue tryptophan 263 (FRK W227; BSK W234; BRK W184) binds to the SH3 domain 
and induces a conformational change in the catalytic domain.  Thus, the tyrosine 416 (FRK 
Y387; BSK Y394; BRK Y342) located in the activation loop cannot be phosphorylated 
which is required for the activation of kinase activity (Ayrapetov et al., 2006). 
 
 
FRK differs significantly from SFKs in that it harbors a putative bipartite nuclear 
localization signal (NLS).  The NLS comprises two clusters of basic amino acids, separated 
by a spacer of nine amino acids (KRLDEGGFFLTRRR motif) in the SH2 (Serfas and 
Tyner 2003) (Figure 2.6).  The mouse and rat orthologs of FRK display myristoylation 
sequences that have been shown to potentiate membrane binding, indicating that the 
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intracellular targets and perhaps the cellular roles may differ across species (Sunitha and 
Avigan 1996; Sunitha et al., 1999).  The cellular and biochemical functions, and the 
physiological roles of FRK have not been fully characterized.  
 
 
Figure 2.6.  Amino acid sequence of human FRK (1-505).  The SH3 domain (42-110) is 
in yellow; SH2 domain (116-208) in blue; kinase domain (234-491) in grey.  The putative 
nuclear localization sequence (168-181) within the kinase domain is outlined.  The 
regulatory C-terminal tyrosine (Y497) is in red. 
 
 
2.2.2 Murine orthologs of FRK 
Bsk (-cell Src-homology tyrosine kinase), also known as Iyk (Intestine tyrosine kinase), 
is highly homologous to the human FRK gene (Thuveson et al., 1995).  Bsk was originally 
identified from insulinoma cells RINm5F by PCR.  The cDNAwas isolated from the 
insulin-producing cell lineTC-1 (Oberg-Welsh and Welsh 1995).  The sequence 
comparison revealed 89% amino acid homology to FRK and 87% nucleotide identity 
(Oberg-Welsh and Welsh 1995), 49% to Src (Martinez et al., 1987) and 49% to murine 
Lyn (Stanley et al., 1991) (Figure 2.5).  Bsk was also isolated from other cell lines, and 
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designated with another independent name Iyk.  The cDNA of Iyk was also obtained by 
screening the primary mammary epithelial cell line 31E, using the PCR fragment amplifed 
from mature mouse resting mammary glands by reverse transcription PCR (RT-PCR) 
(Thuveson et al., 1995).  Another FRK homolog is Gtk (Gastrointestinal tyrosine kinase).  
It was cloned from rat small intestine by RNAse protection analysis (Sunitha and Avigan 
1994).   
The expression of Bsk was detected at low levels in normal mammary gland during 
the estrous cycle and pregnancy, and at undetectable levels in the end-differentiated, 
lactating gland (Thuveson et al., 1995).  Moreover, the expression of Bsk decreased with 
the embryonic development (Thuveson et al., 1995).  Bsk has been observed in intestine, 
especially the jejunum and ileum, with the highest expression levels, among mouse 
epithelial organs such as lung, liver (Oberg-Welsh and Welsh 1995), ovary, placenta, 
kidney and 13 day embryos (Thuveson et al., 1995); while Bsk was absent in the brain, 
heart, spleen and testis (Oberg-Welsh and Welsh 1995).  Gtk was found to be highly 
expressed in the small intestine and stomach, with lower expression seen in the lung, 
kidney, liver, spleen, brain, heart and leg muscle (Sunitha and Avigan 1994).   
In normal breast epithelium, Bsk has been shown to localize to both nucleus and 
cytoplasm during the proliferating follicular phase and luteal phase of menstrual cycle.  
The localization became more nuclear at the luteal phase and predominantly nuclear after 
menopause, indicating that distribution of nuclear and cytoplastic localization depended on 
cell proliferation (Berclaz et al., 2000).  The linkage among the structure, localization and 
function have also been found.  It has been elucidated that the C-terminal tyrosine residues 
Y497/504 of Bsk were responsible for regulation of the kinase activity and subcellular 
localization of Bsk, and the double mutation of Y497/504 both to phenylalanine at the C-
terminus inhibited NIH3T3 cell growth (Oberg-Welsh et al., 1998).  This group also found 
the suppressive function of Y497F and Y497/504F of Bsk on the cell proliferaton of the 
insulin producing cell line, RINm5F cells (Anneren and Welsh 2000).  It has been 
demonstrated that Gtk colocalized with hepatocyte growth factor (HGF) to the brush border 
membrane in the columnar gut epithelia cells, suggesting that Gtk might be involved in the 
HGF-linked pathway (Sunitha et al., 1999).   
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Although the presence of Gtk lead to an increase in the -cell mass, a negative 
regulation of islet cell growth by promoting the phosphorylation of ERK 1/2 and inhibiting 
the phosphorylation of p38 was also observed (Anneren and Welsh 2001).  Further studies 
revealed that Gtk cannot only induce growth arrest following cytokine stimulation, but also 
promote -cell replication after partial pancreatectomy and increases the susceptibility to 
streptozotocin, cooperating with SHB (SRC homology 2 domain adapter protein)  
(Anneren 2002).  In addition, in rat pheochromocytoma cell line PC12, neurite outgrowth 
was induced in the presence of Gtk overexpression (Anneren et al., 2000).  Moreover, Gtk 
has also been detected to correlate with elevated phosphorylation levels of FAK (focal 
adhesion kinase) and SHB as well as  an enhanced association between FAK and SHB, 
indicating that Gtk might play a role in cell differentiation and -cell proliferation (Anneren 
et al., 2000; Anneren et al., 2003).   
Chandrasekharan et al. generated the Iyk-deficient mice.  In these mice models, no 
significant difference was detected in growth rate compared to wild-type models.  They 
also examined the morphology of intestinal epithelium cells and suggested that Iyk was 
redundant for cell differentiation in intestine (Chandrasekharan et al., 2002). 
 
 
2.3 FRK-interacting proteins 
Very few FRK interacting proteins have been identified.  They include: phosphatase and 
tensin homolog (PTEN) (Yim et al., 2009), Retinoblastoma protein (pRb) (Craven et al., 
1995), Src homology 2 domain-containing adapter protein B (SHB) (Anneren 2002) and 
epidermal growth factor receptor (EGFR) (Jin and Craven 2013).  The following sections 
will describe PTEN, pRb, SHB and EGFR in details.   
 
2.3.1 PTEN 
PTEN has been recently shown to be a substrate of FRK (Yim et al., 2009).  The C2 domain 
of PTEN is reported to bind to the SH3 domain of FRK.  FRK can stablize PTEN by 
phosphorylating the Tyr 336 in the C2 domain of PTEN, thereby protecting PTEN from 
ubiquitin-mediated degradation (Yim et al., 2009). 
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PTEN plays an important role in negatively regulating the phosphoinositide 3-
kinase (PI3K) signaling which is involved in the regulation of cell metabolism, 
proliferation and survival (Carracedo and Pandolfi 2008).  PTEN can negatively regulate 
PI3K by converting the PIP3 back to PIP2 on the membrane (Makker et al., 2014).  As a 
lipid phosphatase, PTEN contains a phosphatase, C2 domain, and a lipid-binding domain 
which is responsible for anchoring the protein to the cell membrane, as well as several 
regulatory tyrosines which may modulate cell proliferation when phosphorylated 
(Carracedo and Pandolfi 2008).   
PTEN has been identified as a frequently mutated gene on human chromosome 
10q23, and its expression is lost in various cancers.  Several studies have shown that the 
protein is a potential tumor suppressor (Li and Sun 1997; Li et al., 1997; Steck et al., 1997; 
Yim et al., 2009).  There are also some frequent mutation sites located in the catalytic 
domain, C2 domain and ubiquitinylation region, and these mutations have been found to 
be critically linked to the progression and development of tumors (Eng 2003; Trotman et 
al., 2007).  Mutations in PTEN have been shown to promote its membrane localization, 
thereby promoting the activity of PI3K signaling and impairing the tumor-suppressive 
function in glioblastoma (Walker et al., 2004).  The loss of Pten also contributed to the 
tumorigenesis in mouse models, and both lethal autoimmune disorders and various types 
of epithelial cancers were caused by the Pten allelic deletion (Di Cristofano et al., 1998; 
Di Cristofano et al., 1999).  
It was recently reported that PTEN can be regulated at both transcriptional and post-
translational levels (Salmena et al., 2008).  At the transcriptional level, several signaling 
pathways, including RAS and JNK, were demonstrated to be capable of regulating the 
transcription of PTEN, thereby modulating tumor progression (Beck and Carethers 2007; 
Vasudevan et al., 2007; Xia et al., 2007).  It has been illustrated that the MEK-dependent 
(Mitogen-activated protein kinase kinase-dependent) pathway can also increase both c-Jun 
expression and the binding ability of transcription factor to the PTEN promoter (Hettinger 
et al., 2007; Vasudevan et al., 2007).  At the post-translational level, the phosphorylation 
of several C-terminal tyrosine residues of PTEN was shown to correlate with increased 
protein stability (Georgescu et al., 1999; Vazquez et al., 2000; Torres and Pulido 2001), 
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while the downregulation of Pten stability was observed when the tyrosine residues at other 
sites were phosphorylated (Maccario et al., 2007). 
 
2.3.2 pRb 
pRb, a known tumor suppressor, plays a role in regulating cell differentiation and cell cycle 
(Classon and Harlow 2002).  Being a member of the pocket protein family, at least two 
protein-interacting pockets of pRb have been reported: the A/B pocket and a C-terminal C 
pocket.  The former one is associated with E2Fs transcription factors (Weinberg 1995), and 
the latter is associated with c-Abl, which is a tyrosine kinase (Craven et al., 1995).   
pRb has also been reported to associate with FRK.  The expression of FRK was 
detected at the highest level in the G1 and S phases, and at a low level during mitosis, 
indicating the important role of FRK in cell cycle control (Cance et al., 1994; Pendergast 
1996).  Several studies have indicated that the SH3 domain of FRK is responsible for 
binding to the A/B pocket region of pRb, causing a breast cancer cell growth arrest during 
the G1 and S phases of cell cycle both in vitro and in vivo (Thuveson et al., 1995; 
Chandrasekharan et al., 2002; Meyer et al., 2003).  However, the enzymatic activity of 
FRK was not affected by the binding with FRK and pRb (Pendergast 1996).  Hence, FRK-
pRb binding may enhance the association of FRK with its substrates which may negatively 
regulate cell proliferation (Yim et al., 2009). 
 
2.3.3 SHB 
SHB has been reported as a ubiquitously expressed protein (Welsh et al., 1998).  This 
protein contains N-terminal proline-rich motifs (Karlsson et al., 1995), followed by a 
PhosphoTyrosine Binding (PTB) domain (Welsh et al., 1998; Lindholm et al., 2002), four 
tyrosine residues (Lu et al., 2000; Lindholm et al., 2002), and a C-terminal SH2 domain 
(Karlsson et al., 1995).  SHB has been previously demonstrated to regulate several 
receptors via SH2 domain binding, including fibroblast growth factor receptor-1 (FGFR-1) 
(Karlsson et al., 1995; Cross et al., 2002), T cell receptor (Lindholm et al., 1999), Platelet-
Derived Growth Factor (PDGF) receptor (Karlsson et al., 1995), and Vascular Endothelial 
Growth Factor Receptor-2 (VEGFR-2) (Holmqvist et al., 2004). 
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Furthermore, SHB participates in receptor tyrosine kinase signaling through 
forming the signaling complex upon extracellular stimuli, thereby regulating apoptosis, 
proliferation, differentiation and cytoskeletal physiology (Anneren et al., 2003; Kriz et al., 
2003; Kriz et al., 2006; Saldeen et al., 2006).  It has been reported that in SHB-
overexpressing rat pheochromocytoma PC12 cells, phosphorylation levels of SHB 
increased upon the Nerve Growth Factor (NGF) stimulation, resulting in enhanced neurite 
outgrowth (Karlsson et al., 1998).  SHB has also been reported to associate with FRK.  For 
example, increased phosphorylation levels of SHB were observed in cells overexpressing 
Gtk (Anneren et al., 2003).   
 
2.3.4 EGFR 
EGFR plays an important role in the proliferation of certain types of tumor cells (Lemmon 
and Schlessinger 2010).  The internalization of EGFR occurs via the ubiquitination and 
phosphorylation upon the extracellular stimuli, resulting in either degradation or reuse of 
EGFR (Sorkin and Goh 2008).  FRK was recently reported to associate with the EGFR (Jin 
and Craven 2013).  This work also revealed that the FRK-EGFR binding was directly 
through the SH2 and SH3 of FRK and the Y1173 located on EGFR which was required for 
ERK activation and EGFR internalization (Jin and Craven 2013).  Moreover, Grb2 was 
also found to bind to EGFR and form a complex with EGFR subsequently, suggesting that 
FRK may associate with the EGFR-Grb2 complex (Jin and Craven 2013).  
 
2.4 Intracellular localization of FRK 
Unlike other Src-related kinases, human FRK has been identified as a nuclear protein 
(Chandrasekharan et al., 2002).  However, its intracellular localization has still been 
controversial.  Human FRK has been reported to be expressed predominantly in the nuclei 
in COS7 monkey kidney cells (Cance et al., 1994), while it has been shown to have a 
perinuclear localization in BT474 breast cancer cells and some other cell lines (Meyer et 
al., 2003).  It is worth mentioning that the structure of FRK provides a strong evidence for 
this perinuclear localization.  SFKs have an N-terminal myristoylation motif MGXXXS/T 
required for plasma membrane-targeting.  This motif is not conserved in human FRK 
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(Chandrasekharan et al., 2002).  FRK has a glutamine (Q) instead of a conserved serine (S) 
residue at position 6 of its N-terminal sequence (Chandrasekharan et al., 2002), which may 
explain the absence of membrane-anchorage (Kaplan et al., 1990; Brauer and Tyner 2009).  
Moreover, the SH2 domain of FRK has been found to contain a putative bipartite nuclear 
motif (KRXXXXXFFXXRRR), supporting the potential nuclear localization of FRK 
(Craven et al., 1995).   
Since human FRK has been detected in the nucleus as well as the cytoplasm in the 
breast cancer cell line BT-20, it is therefore possible that the localization of FRK may vary 
in different cell lines (Cance et al., 1994).  Additionally, a recent study has also shown that 
the intracellular localization of FRK was predominantly in the perinucleus and cytoplasm 
(Pilati et al., 2014).   
Unlike human FRK, the murine orthologs (Bsk and Gtk) possess both the consensus 
myristoylation motif and nuclear localization signal (Chandrasekharan et al., 2002).  
Moreover, murine ortholog Bsk, has also been detected in both the nucleus and cytoplasm 
(Chandrasekharan et al., 2002).  Interestingly, although Gtk possesses two different 
localization signal motifs (the nucleus and membrane), it has been found to predominantly 
localize to the plasma membrane instead of nuclear localization in epithelial cells (Sunitha 
and Avigan 1996; Sunitha et al., 1999).   
 
2.5 Functional roles of FRK in cancer 
Several lines of evidence illustrate that FRK has a potential inhibitory effect on the tumor 
progression.  30% of primary human breast carcinomas displayed loss of heterozygosity 
(LOH) at the long arm of chromosome 6 (6q 21-23),  which is where the FRK gene locates 
(Sheng et al., 1996).  This FRK chromosomal region also displayed allelic loss in 40% of 
melanomas (Becher et al., 1983; Millikin et al., 1991).  In addition, in certain ovarian 
cancers, genetic deletions in 6q have also been detected (Ehlen and Dubeau 1990).  These 
pieces of evidence suggest the potential tumor suppressor function of FRK. 
It has been reported that FRK overexpression in both epithelial and mesenchymal 
cells results in growth arrest, suggesting that FRK is a negative regulator of cell 
proliferation (Meyer et al., 2003).  In support of this finding, FRK depletion was shown to 
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induce transformation of non-tumorigenic MCF-10A epithelial cells (Yim et al., 2009).  
Exogenous FRK has been shown to induce an inhibition in both colony formation and cell 
growth in NIH 3T3 fibroblasts (Craven et al., 1995).  Consistent with the previous results, 
the same inhibitory effect has also been shown in breast cancer cell lines BT474 and MCF-
7 (Craven et al., 1995).  The anti-proliferative properties of FRK have also been studied in 
other types of cancer.  Over-expression of FRK has been found to arrest the HeLa cells in 
the G1 phase of the cell cycle (Chandrasekharan et al., 2002).  In human glioma cell lines 
U251 and U87, FRK has also been shown to contribute to the suppression of cell migration 
and invasion.  In the same study, mRNA comparison between non-tumorous and tumorous 
samples revealed that FRK is significantly highly expressed in non-tumor samples, 
suggesting FRK may possess a potential tumor suppressive function (Zhou et al., 2012).  
As well, FRK has been shown to associate with Cdc2 and Cdk4, but not with Cdk5, Cdk6 
or Cdk7 (Pendergast 1996), but the significance of the associations is unknown.  These 
data all confirmed an inhibition to cell growth induced by overexpression of FRK (Craven 
et al., 1995).   
Accumulating evidence also indicated this regulatory role of both human and rodent 
FRK in the process of cancer was through the regulation of signal transduction.  A series 
of FRK-interacting proteins have been recently identified to be involved in cell growth 
regulation.  Mechanistically, the overexpression of FRK has been found to inhibit cell 
proliferation by phosphorylating and preventing tumor suppressor PTEN from 
ubiquitination and degradation.  The stabilization of PTEN after phosphorylation on Tyr 
336 resulted in the inhibition of the PI3K/Akt signaling pathway, which suppressed 
downstream signaling responsible for the regulation of cell proliferation, migration and 
differentiation (Yim et al., 2009).  SHB has been confirmed to interact with FRK possibly 
via the SH3 domain of FRK which targeted proline-rich motifs and/or SHB phosphorylated 
tyrosine binding to the SH2 domain of FRK (Anneren et al., 2003).  The overexpression 
of rat FRK resulted in TRKA induction, followed by a subsequent increase in SHB 
phosphorylation and FAK expression (Anneren et al., 2003).  The interaction between SHB 
and FAK triggered the binding of CRKII-C3G complex to phosphorylated SHB via the 
SH2 domain of CRKII, thereby stimulating the neurite outgrowth through activating 
several RAP1-involved downstream signaling pathways (Anneren et al., 2003).  Rat FRK 
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orthologs also played an essential role in regulating the -cell proliferation (Welsh et al., 
1999; Anneren and Welsh 2001).  It has been reported that this regulation of cell growth 
may be through insulin receptor substrate-2 (IRS-2)-RAS-MAPK pathway (Anneren et al., 
2003).  An elevated basal IRS-1/IRS-2 phosphorylation level (Anneren and Welsh 2002; 
Welsh et al., 2002) and a consequent increase in MAPK activity (Anneren and Welsh 2001) 
were both detected due to the overexpression of both FRK and SHB in -cell.  FRK has 
been also reported to interact with the pRb, via binding to the A/B pocket domain of pRb 
in the human breast cancer cell lines BT474 and SK-BR-3 (Craven et al., 1995).  pRb acted 
as a tumor suppressor which regulated cell cycle during the G1 phase of the mitosis 
(Burkhart and Sage 2008).  The interaction between tumor suppressor protein pRb and 
FRK was first detected in both G1 and S phases of the cell cycle in the SK-BR-3 breast 
cancer cell line, suggesting that FRK-Rb association may contribute to the regulation of 
the cell cycle (Yim et al., 2009).   
Human FRK has also been reported to be able to phosphorylate Y530 at the C-
terminal region of Src which is responsible for negative regulation, indicating FRK may 
exert an important role in signaling (Cance et al., 1994).  A recent study revealed that FRK 
also regulated the signaling activity of receptor tyrosine kinases.  It was demonstrated that 
FRK interacted with EGFR by directly binding to EGFR via the SH2 and SH3 domains of 
FRK, forming a complex upon EGF stimulation (Jin and Craven 2013).  The EGFR 
expression on the cancer cell membrane was found to be suppressed, indicating the 
inhibitory function of FRK on EGFR signaling pathway in cancer (Jin and Craven 2013).  
Similar to EGFR signaling, cytokine-stimulated signaling has also been illustrated to be 
affected by FRK in human malignant glioma.  It is suggested that FRK exerted a negative 
control in glioma cell migration and invasion through down-regulating the JNK/c-Jun 
signaling; a part of the MAPK pathway which is mainly required for cell survival, 
proliferation and differentiation.  Therefore, JNK has been suggested to be one of the 
cellular targets of FRK (Zhou et al., 2012).  These studies all support the negative-
regulatory properties of FRK in signal transduction although the entire complex 
mechanism of FRK regulation in the signaling has not been fully investigated.  
Furthermore, it is not known how the activation of FRK can potentiate its cellular function. 
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An oncogenic role of FRK has also been proposed in a few studies.  The FRK gene 
has been previously found to fuse with ETV6, ETS transcription factor, endowing the fused 
protein with oncogenic properties in acute myelogenous leukemia (Hosoya et al., 2005) 
although the mechanism of switching from tumorigenesis to tumor-suppressive function 
still remains unknown.  More recently, high expression levels of FRK of protein and 
transcription have been detected in 4 human hepatocellular carcinoma (HCC) cell lines 
including HepG2, Hep3B, PLC/PRF/5 and Huh7 (Chen et al., 2013).  In that study, the 
authors found that the introduction of FRK induced an increase in cell proliferation, 
invasion and transformation in Hep3B cell lines.  It was also recently demonstrated that 
FRK promoted the cell proliferation of HCC Hep3B cell line (Pilati et al., 2014), 
suggesting FRK may be oncogenic depending on the tissue contexts. 
 
2.6. Objectives and rationale 
 
2.6.1 Rationale 
FRK has been shown to localize to the nucleus and play key roles in the regulation of 
cellular function including cell survival, proliferation and migration.  FRK is a candidate 
tumor suppressor and its overexpression in mammary gland cells was recently reported to 
inhibit cell growth via interacting, phosphorylating and stabilizing the tumor suppressor 
PTEN.  However, the mechanism of FRK activation has not been fully explored.  We 
hypothesized that like Src-family kinases, the activity of FRK is regulated by 
intermolecular interaction involving a C-terminal tyrosine residue.  As well, much remains 
to be clarified about the functional differences between the proto-oncogenic Src kinase, for 
example, and the tumor suppressor activity of FRK.  What is the expression pattern of FRK 
in the breast cancer cells and breast carcinomas?  What is the intracellular localization 
pattern of FRK in breast cancer cells?  Is stable overexpression of FRK in FRK-negative 
breast cancer cells sufficient to inhibit cell proliferation, migration and anchorage-
independent growth?  What signaling pathways are regulated by FRK?  What is the role of 
FRK enzymatic activity in these processes? 
A previous study demonstrated that the constitutive activation of FRK was achieved 
by mutating the C-terminal tyrosine 497 usually to phenylalanine (Y497F).  We 
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hypothesize that the activity of FRK is essential in the regulation of its cellular function.  
The objective of this project is to investigate the effect of FRK activity on breast cancer 
cell proliferation and migration.  We generated stable cell lines expressing the 
constitutively active FRK variant (Y497F) and examined the effect on cell proliferation, 
migration, invasion and colony formation.  We also used kinome analysis to identify and 
validate FRK regulated signaling pathways and intermediates.  We found that FRK-Y497F 
is significantly more active than FRK-WT and that the presence of FRK-Y497F resulted 
in a marked suppression of both cell proliferation and migration.  Finally, we observed that 
both FRK-WT and FRK-Y497F inhibited the constitutive activation of several signaling 
molecules including STAT3. 
 
2.6.2 Hypothesis and Objectives  
2.6.2.1 Hypothesis 
FRK activation suppresses cell proliferation, migration, invasion and cell formation via 
inhibition of specific signaling pathways in breast cancer cells. 
 
2.6.2.2 Specific Objectives 
1. To determine the expression and subcellular localization of FRK in breast cancer 
cells. 
2. To clone and characterize constitutively active FRK mutants and generate stable 
cell lines. 
3. To determine the effect of stable expression of FRK on the migration, proliferation 
and transformation of breast cancer cell lines. 
4. To identify FRK-regulated signaling pathways. 
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3 MATERIALS AND METHODS 
3.1 Reagents 
All the reagents used in experiments are listed in Table 3.1.  Names and locations of 
suppliers are listed in Table 3.2.  The information regarding the primary antibodies used 
in the experiments is listed in Table 3.3. 
Table 3.1.  List of reagents and suppliers. 
 Reagents Suppliers	
Inorganic 
and 
Organic 
Reagents 
Acrylamide, 0341	 AMRESCO	
Aprotinin, A6279	 Sigma-Aldrich	
Ammonium persulfate (APS), A3678	 Sigma-Aldrich	
Bisacrylamide, 0172	 AMRESCO	
Crystal violet, 65092A-95 EMD 
4’, 6-diamidino-2-phenylindole (FITS), D9542 Sigma-Aldrich 
Enhanced Chemiluminescence Substrate (ECL),  NEL 
104001EA PerkinElmer 
Gelatin, G1890 Sigma-Aldrich 
Glycine, 0167 AMRESCO 
Laemmli sample buffer, S3401	 Sigma-Aldrich 	
MEM Vitamin Solution, 11120-052 Gibco 
Methanol, MX0485 EMD 
SDS, 151-21-3 Sigma-Aldrich 
Difco™ skim milk, 232100 BD 
Sodium azide, S8032 Sigma-Aldrich 
Sodium chloride (NaCl), 0241 AMRESCO 
Tris, 0826 AMRESCO 
Triton™ X-100, X-100 Sigma-Aldrich 
TWEEN® 20, 0777 AMRESCO 
Paraformaldehyde, PX0055-3 EMD 
Polyethylenimine, 25987-06-8 Sigma-Aldrich 
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phenylmethylsulfonyl fluoride (PMSF), P7626 Sigma-Aldrich 
N,N,N’,N’-Tetramethylethylenediamine (TEMED), 
87689 
Sigma-
Aldrich 
Bacterial 
Culture  
Ampicillin, 0339 AMRESCO	
Trptone, 1.07213.1000 EMD 
Fermtech® Yeast Extract, 1.11926.1000	 EMD	
Kanamycin sulfate, 0408 AMRESCO 
Lysogeny Broth (LB) agar, L2897	 Sigma-Aldrich	
Cell 
Culture 
    Dulbecco’s Modified Eagle Medium (DMEM), 
SH30022.01	
Thermo 
Fisher 
Scientific	
Fetal Bovine Serum (FBS), SH30397.03	
Thermo 
Fisher 
Scientific	
Trypsin-EDTA, T4049	 Sigma-Aldrich	
Cloning 
Agarose I™, 0710	 AMRESCO	
Alkaline phosphatase, M0290S NEB 
Adenosine Triphosphate (ATP), A1205	 Teknova	
dNTP, D0056	 GeneScript	
100bp DNA ladder, N3231S NEB 
1kb DNA ladder, N3232S NEB 
T4  DNA ligase, M0202S	 NEB	
Taq Polymerase, M0273S	 NEB	
 
 
Table 3.2.  List of names and Addresses of the Suppliers. 
Suppliers	 Locations 
AMRESCO	 North York, Ontario, Canada 
BD Mississauga, Ontario, Canada 
Bio-Rad Hercules, California, USA 
Cell signaling Whitby, Ontario, Canada 
Corning NY, USA 
Dojindo Rockville, Sunnyvale, USA 
EMD	 Madison, Wisconsin, USA 
GeneScript Piscataway Township, New Jersey, USA 
Gibco Burlington, Ontario, Canada 
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Invitrogen Burlington, Ontario, Canada 
New England Biolab (NEB)	 Mississauga, Ontario, Canada 
Olympus Richmond Hill, Ontario, Canada 
Pall Corporation Washington, NY, USA 
PerkinElmer	 Boston, Massachusetts, USA 
Qiagen Mississauga, Ontario, Canada 
Santa Cruz Santa Cruz, California, USA 
Sigma-Aldrich	 Oakville, Ontario, Canada 
Teknova Hollister, California, USA 
Thermo Fisher Scientific Whatham, Massachusetts, USA 
VWR	 Mississauga, Ontario, Canada 
Whatman	 Piscataway, New Jersey, USA 
 
 
Table 3.3.  List of the antibodies and suppliers (R refers to rabbit; M refers to mouse). 
Antibodies (Species) and working dilution Suppliers
-Tubulin (R) 1:1000	 Santa-Cruz	
FRK (m) 1:1000 Santa-Cruz 
Phospho-tyrosine (pY20) (m) 1:1000 Santa-Cruz 
BRK (m) 1:1000 Santa-Cruz 
Sam68 (R) 1:1000 Santa-Cruz 
GFP (R) 1:1000 Santa-Cruz 
AKT (R) 1:1000	 Cell signaling	
Phospho-AKT (R) 1:1000 Cell signaling 
MEK 1/2 (R) 1:1000	 Cell signaling	
Phospho-MEK 1/2 (R) 1:1000 Cell signaling 
ERK 1/2 (m) 1:1000	 Cell signaling	
Phospho-ERK 1/2 (R) 1:1000 Cell signaling 
P38 MAPK (R) 1:1000	 Cell signaling	
Phospho- P38 MAPK (R) 1:1000  Cell signaling 
STAT3 (R) 1:1000 Cell signaling 
Phospho-STAT3 (R) 1:1000 Cell signaling 
JNK (m) 1:1000	 Santa-Cruz	
Phosphor-JNK (m) 1:1000	 Santa-Cruz	
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3.2 Cell lines and Cell culture 
Human embryonic kidney 293 (HEK293) cells and breast cancer cell lines (AU565, BT20, 
MDA-MB-231, MDA-MB-468, MDA-MB-435, SKBR3, T47D, HBL100, MCF7, Malme 
3M) were purchased from ATCC (American Type Culture Collection).  All the cells used 
in the experiment were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS) and incubated in a humidified CO2 
incubator (Thermo Fisher Scientific, HERAcell 150i) with 5% CO2 at 37Ԩ.  Cells were 
detached by 0.25 % (w/v) Trypsin-EDTA and split into new culture plates when the 
confluence reached 85-95 %. 
 
3.3 Cloning of human FRK mutants 
3.3.1 Plasmids and cloning sites 
FRK-WT (wild type) and FRK-K262M were obtained from Dr.Lukong’s lab.  FRK-Y497F 
was amplified by a polymerase chain reaction (PCR) using purified FRK-WT fragment as 
a template.  For the GFP-FRK constructs (GFP-FRK-WT, GFP-FRK-K262M, and GFP-
FRK-Y497F), purified PCR products (FRK-WT, FRK-K262M, and FRK-Y497F) were 
amplified using the corresponding primers, and sub-cloned into the XhoI and PstI sites of 
the plasmid pEGFP-C1, respectively.  Using the same strategy, the retroviral LPC-FRK-
WT was constructed by inserting FRK into the XhoI site of the retroviral plasmid pLPC.  
LPC-FRK-Y497F was mutated by site-directed mutagenesis using LPC-FRK-WT as a 
template.  These LPC-FRK mutants were used for further generation of stable cell lines 
(refer to section 3.4).  Primers used in the experiments were purchased from Invitrogen.  
All the restriction enzymes and the corresponding enzyme buffers were purchased from 
New England Biolabs (NEB).  Designed primers and restriction enzyme sites are listed in 
table 3.4.  Plasmids pEGFP-C1 and pLPC were both generously provided by Dr. Stephane 
Richard (McGill University, Canada).  The general cloning procedure is briefly described 
in section 3.3.2.  
 
3.3.2 General cloning technique 
3.3.2.1 PCR, digestion, purification and mutagenesis 
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Single PCR reaction was set up in a total volume of 50 µL, containing 1.25 units Taq 
polymerase with 10× Standard Taq reaction buffer, 10 mM dNTPs, 10 µM forward primer, 
10 µM reverse primer, 50-100 µg template DNA, and nuclease-free water.  The 
thermocycling conditions for PCR amplification consisted of 2 minutes initial denaturation 
at 95Ԩ, followed by 30 cycles (30 seconds at 95Ԩ, 30 seconds at annealing temperature, 
and 15 minutes at 68Ԩ), and 5 minutes final extension at 68Ԩ.  Site-directed mutagenesis 
was performed by using KAPA HiFi™ HotStart DNA polymerase system 
(KAPABIOSYSYTEMS, KK2101) following the manufacturer’s standard protocol.  PCR 
was performed using the C1000™ Thermal Cycler (Bio-Rad, 185-1148).  Vectors and 
inserts were both digested with restriction enzymes, and analysed by 1% (w/v) agarose gel 
electrophoresis.  The inserts and linearized vectors were then extracted from the agarose 
gel.  To prevent the re-circularization of vectors, 1-2 units of alkaline phosphatase were 
added to remove the 5’ phosphate groups when the single digestion was applied before the 
purification step.  Digested vectors were incubated with alkaline phosphatase and 
NEBuffer 3 in a total volume of 20 µL at 37Ԩ for 1 minute. The subsequent PCR and gel 
purification prior to ligation were conducted by using the QIAquick PCR Purification Kit 
(Qiagen, 28104) and the QIAquick Gel Extraction Kit (Qiagen, 28704) following the 
manufacturer’s instructions.   
 
Table 3.4.  List of sequence and designed restriction enzyme sites of the primers. 
Mutants	 Sequences 
Designed 
Restrict 
Enzyme 
GFP-FRK-WT 
For	
5’-AAACTCGAGGCCACCATGAGCAACATCTGT- 
3’ XhoI 
GFP-FRK-WT 
Rev 5’-AATCTGCAGTCATCTTATGAAGTT-3’ PstI 
GFP-FRK-
Y497F For 
5’-AAACTCGAGGCCACCATGAGCAACATCTGT- 
3’ XhoI 
GFP-FRK-
Y497F Rev 
5’-
AATCTGCAGTCATCTTATGAAGTTATTTGCATC
TGAAAATGAAGA-3’ 
PstI 
LPC-FRK-WT 
For 
5’-AAACTCGAGGCCACCATGAGCAACATCTGT-
3’ XhoI 
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LPC-FRK-WT 
Rev 5’-GCCCTCGAGTCATCTTATGAAGTTATTTGC-3’ XhoI 
LPC-FRK-
Y497F For 
(Mutagenesis)	
5’- 
GAAACAGACTCTTCATTTTCAGATGCAAATAA
CTTC-3’ 
N/A 
LPC-FRK-
Y497F Rev 
(Mutagenesis) 
5’-GAAGTTATTTGCATCTGAAGAGTCTGTTTC-
3’ N/A 
Note that the restriction sites are underlined, and mutation sites of mutagenesis are 
highlighted in bold. 
  
3.3.2.2 Ligation 
The purified vectors and restriction inserts were ligated by using 1× T4 DNA ligase 
reaction buffer, 1 µL T4 DNA ligase, 1 µL Adenosine Triphosphate (ATP), and nuclease-
free water in a total reaction volume of 20 µL.  The ligation mixture was incubated at 16Ԩ	
overnight.  Ligated plasmids were transformed into E.coli DH5 competent cells the next 
day.  Competent cells treated by calcium chloride were prepared using previous lab 
protocols. 
 
3.3.2.3 Transformation of E.coli 
The DNA of interest was transformed into E.coli DH5 cells which were used as a host.  
5 µL ligation mixture was added into 50 µL competent cells once the cells were thawed, 
leaving it on ice for half an hour.  Subsequently, 45 seconds exposure to a heat shock at 
42Ԩ and 2 minutes cold shock were applied.  500 µL antibiotic-free LB Broth medium, 
containing Tryptone, Fermtech® Yeast Extract, NaCl and ddH2O, was added into mixture, 
and the mixture was incubated in a shaker at 37Ԩ for 1 hour.  Following centrifugation at 
20,000 × g for 30 seconds, 450 µL cell supernatant was removed.  The remaining cells 
were resuspended by a pulse vortex, and plated on LB agar plates containing the 10% 
appropriate antibiotic(s) (kanamycin for pLPC; ampicillin for pEGFP-C1). The selectable 
antibiotic resistance markers on plasmids facilitated the screening of the recombinants.  
The recombinants which the plasmid DNA was successfully transformed into bacterial was 
selected by picking up single colonies after 16-18 hours culture at 37Ԩ.  The plasmid DNA 
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was prepared and sent for sequencing to verify the mutations.  Sequencing was performed 
by National Research Council Canada DNA sequencing facility (Saskatoon, SK).  
 
3.4 Generation of stable cell lines 
Two stable cell lines were generated by the transfection of FRK-WT and FRK-Y497F 
constructs into MDA-MB-231, respectively.  Using a similar cloning strategy mentioned 
previously (refer to section 3.3.2), two FRK fragments (FRK-WT and FRK-Y497F) were 
subcloned into the Xho I site in pLPC retroviral vector with a puromycin selection marker, 
respectively.  HEK 293-derived Phoenix packaging cells were transfected with the 
retroviral constructs, and the viral supernatant was used to infect MDA-MB-231 cells.  
pLPC-containing cells were selected with puromycin.  All untransduced MDA-MB-231 
cells died within 7 days of selection.  The selected stable cell lines were cultured in 
puromycin for 4 weeks.  Stable cells were obtained to measure the FRK expression level 
by Western blot analysis using a commercial FRK antibody generated from a C-terminal 
epitope (Table 3.4).  
 
3.5 Cell assays 
3.5.1 Cell transient transfection 
Human FRK and its mutants were introduced into HEK 293 cell using transient transfection 
with polyethylenimine (PEI) (Polyscience, Warrington, PA, USA).  PEI stock solution was 
prepared at a concentration of 1 mg/mL in water.  Aliquots were stored at -20Ԩ.  A day 
prior to transfection, HEK 293 cells were seeded into 6-well plate (BD, 353046) in DMEM.  
Transfection was performed when cells were at 70% confluence.  5 µg DNA of interest 
(refer to section 3.3.2) was mixed with the 107.5 µL 0.15 M NaCl by a gentle vortex for 
10 seconds.  15 µL 1% PEI was then added into the mixture followed by another pulse 
vortex for 10 seconds, and then the mixture was incubated at room temperature for 20 
minutes.  The medium in the 6-well plate was replaced with fresh pre-warm DMEM (1 
mL/well) and the PEI mixture was added dropwise into each well and distributed evenly 
in the well.  The efficiency of the transfection was monitored by GFP expression after 24-
hour incubation if the DNA was cloned with GFP tag. 
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3.5.2 Cell lysate preparation 
The whole procedure was conducted at 4Ԩ before adding the Laemmli sample buffer.  
Cells were scraped off from one 10 cm culture plate, transferred to pre-cooled micro-
centrifuge tubes and washed with ice-cold PBS for two times by centrifuging at 750 ×	g 
for 5 minutes.  Lysis buffer (10% Triton, 1.5 M NaCl, 1 M Tris [pH 7.4], aprotinin, 100 
mM phenylmethylsulfonyl fluoride, and cold dH2O) was used to lyse cells for 30 minutes 
on ice.  Cell debris were removed by a full speed centrifugation for 15 minutes, and protein 
concentration was measured by the Lowry’s assay. Then 2× Laemmli sample buffer was 
added to the lysates and the total lysates were boiled at 100Ԩ for 5 minutes.  Prepared cell 
lysates were stored at -20Ԩ. 
 
3.5.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
Proteins were separated by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) using vertical Mini-PROTEAN® Tetra cell electrophoresis system (Bio-Rad 
165-8006).  A gel of 1.5 mm thickness was clamped between a short plate and a spacer 
plate, and the casting frame was assembled on casting stands.  Based on the molecular 
weight of target proteins, the 10% resolving gel was chosen for SDS-PAGE.  The 10% 
resolving gel consists of dH2O, 375 mM Tris-HCl (pH 8.8), 30% (w/v) 
acrylamide/bisacrylamide (29:1), 0.4% (w/v) SDS and 0.16% (w/v) ammonium persulfate, 
and 0.1% N,N,N’,N’-Tetramethylethylenediamine.  Stacking gel consisted of dH2O, 0.5 M 
Tris-HCl (pH 6.8), 30% (w/v) acrylamide/bisacrylamide (29:1), 0.4% (w/v) SDS and 
0.16% (w/v) ammonium persulfate, and 0.1% N,N,N’,N’-Tetramethylethylenediamine.  
After the solidification of the resolving gel, appropriate well-forming combs (10-well and 
15-well) were inserted in the stacking gel according to the loading volume of the samples.  
Preheated samples and ColorPlus prestained protein ladder (NEB, P7711S) were loaded 
when the polymerization of the gel was completed.  SDS-PAGE was performed within 1× 
running buffer (0.1% SDS, 25mM Tris, 192 mM glycine, and dH2O; pH 8.3) at a constant 
voltage of 125 V for 90 minutes at room temperature.  Subsequently, the gel was analyzed 
by Western blot analysis (refer to section 3.5.4). 
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3.5.4 Western blot analysis  
The transfer stack was prepared as follows: the SDS-PAGE gel was overlayed with the 
BioTrace™ nitrocellulose membrane (Pall Corporation, P/N 66485), and was sandwiched 
between 3 sheets of 3 MM filter paper (Whatman 3030-6189).  The nitrocellulose 
membranes were pre-soaked in the transfer buffer (20% methanol, 25 mM Tris, 192 mM 
glycine, and dH2O; pH 8.3) at 4Ԩ for 15 minutes.  For transferring proteins to the 
nitrocellulose membrane, the prepared transfer stack was placed in Mini Trans-blot® 
electrophoretic transfer apparatus (Bio-Rad, 170-3930) within transfer buffer, and then a 
constant voltage of 100 V was applied for 80 minutes at 4Ԩ. 
The transferred nitrocellulose membrane was soaked in blocking solution (5% 
Difco™ Skim Milk, 0.05% sodium azide, and 1× TBST) at room temperature for 25 
minutes, followed by a brief rinse with 1× TBST and incubation with primary antibody 
overnight at 4Ԩ.   The next day the membrane was washed with 1× TBST (TBS [10×], 
TWEEN® 20, and dH2O) three times, 15 minutes each, and was then incubated with 
corresponding secondary antibody at room temperature for 40 minutes.  Thereafter, three 
washes of TBST, 5 minutes each, were applied again.  The western blot images were 
acquired using a signal development technique with enhanced chemiluminescence 
substrate according to the manufacturer’s instruction.  The density of the bands was 
analyzed by image J, and the numbers given under the bands were all normalized to their 
corresponding controls.  This technique was used for analyzing all of the data obtained in 
experiments.  
 
3.5.5 Subcellular fractionation 
Subcellular fractionation was performed using the ProteoExtract Subcellular Proteosome 
Extraction Kit (EMD, 539790) following the company’s recommendations.  Briefly, cells 
cultured in 10 cm dishes were washed in 2 mL wash buffer (at 4Ԩ	for 2 minutesሻ supplied 
with the kit.  The cells were then subjected to a centrifugation at 750 ×	g for 5 minutes and 
the supernatant was discarded.  The cells were washed to insure the quality before 
fractionation, as previously described.   
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The fractionation process was started by incubating the cells with 1 mL extraction 
buffer I and 5 µL protease inhibitor cocktail (supplied in the kit).  Cells were then incubated 
at 4Ԩ for 10-minute.  A gentle centrifugation was required for isolating the cytosolic part 
which was obtained in the supernatant.  The remaining mixture was mixed with 1 mL 
extraction buffer II and 5 µL protease inhibitor cocktail (supplied in the kit) and were 
incubated at 4Ԩ for 30 minutes.  The membrane fraction in the supernatant was isolated 
by a gentle centrifugation.  To obtain the nuclear fractions, 500	µL extraction buffer III, 5 
µL protease inhibitor cocktail and 1.5 µL Benzonase Nuclease (supplied in the kit) were 
all added into the rest of mixture.  A 10-minute incubation at 4Ԩ	and a subsequent gentle 
centrifugation were applied.  The supernatant was collected as the nuclear fractions.  500	
µL extraction buffer IV and 5 µL protease inhibitor cocktail (supplied in the kit) were then 
added into the remaining mixture.  Lastly, the cytoskeletal matrix was isolated. 
 
3.5.6 Immunofluorescence 
This technique was performed based on the protocol described in a previous study (Miah 
et al., 2012).  Immunofluorescence was performed on cells fixed on the coverslip.  The 
whole procedure was carried out at room temperature.  Cells were incubated in 2% (w/v) 
paraformaldehyde diluted in PBS for fixation for 20 minutes, followed by permeabilization 
with 1% Triton™ X-100 for 20 minutes.  After two PBS rinses, cells were incubated with 
primary antibody for 1 hour.  Two PBS washes were applied again followed by 1.5-hour 
secondary antibody staining conjugated with fluorescein isothiocyanate, covered by a foil 
to avoid the light.  4’, 6-diamidino-2-phenylindole (FITS) staining was used to indicate the 
nucleus.  Immunofluorescence was examined using a fluorescence microscope (Olympus, 
1X51).  Images were photographed at 40X magnification. 
 
3.5.7 In vitro proliferation assay 
Cell proliferation was assessed using a Cell Counting Kit-8 (CCK-8) (Dojindo, CK04-05) 
according to the manufacturer’s protocol.  CCK-8 contains water-soluble tetrazolium salts 
(WSTs) (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium) which can be reduced by dehydrogenase and form an orange water-soluble 
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formazan dye, indicating cell mitochondrial viability.  Exponentially growing stable cells 
were collected and seeded into 96-well plates (BD, 353077) in 100 µL culture medium 
(1000 cells/well).  Control groups without cells were set up.  The cell proliferation assay 
was designed for a period of 4 days.  After 0, 24, 48, 72 and 96 hours, 10 µL CCK-8 
solution was added into each well and then the cells were incubated for 2 hours.  Following 
treatment with CCK-8, absorbance at 485 nm was measured using a POLARStar OPTIMA 
microplate reader (BMG Labtech, 413-1040).  Each independent experiment was repeated 
six times.  
 
3.5.8 Wound-healing assay 
A confluent monolayer of cells was wounded by scratching a cross on a 10 cm cell culture 
plate with a 1000 µL sterile pipette tip.  The old culture medium was then aspirated and 
replaced with new culture medium supplemented with 10% FBS.  The center of wound 
was photographed by using an inverted microscope (Olympus, CK2) at time points of 0, 
12, 18, 24 and 36 hours.  The percentage of open area was analyzed and quantified by the 
TScratch software (Geback et al., 2009).  Each independent experiment was repeated at 
least three times. 
 
3.5.9 Invasion assay 
Cell invasion assay was performed by using transwell plates incorporating a polycarbonate 
membrane with 8.0 µm size pore (Corning, 3422) following the modified method which 
was originally described in a previous study (Miah et al., 2012).  Inserts were precoated 
with 100 µL 0.15% gelatin and incubated at 37 Ԩ	for 1 hour to produce a three-dimensional 
gel.  Cells were counted and resuspended (1×105 cells/well) in serum-free culture medium 
and added into the inserts.  Each insert was placed in the lower chamber containing 10% 
FBS culture medium.  Following 4 hours incubation, culture medium in insert and chamber 
were removed and non-migrated cells were swabbed by Q-tips from the upper surface of 
the insert.  The membrane was fixed with 20% methanol for 30 minutes at room 
temperature.  Thirty minutes crystal violet staining on cells that attached to the 
polycarbonate membrane at the bottom of insert was used to evaluate the invasive ability.  
Each experiment was repeated three times. 
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3.5.10 Soft agar assay 
0.61% (w/v) semisolid bottom agar containing 10% FBS culture medium was prepared and 
poured on 6 cm cell culture plates (Sigma-Aldrich, D8054).  MEM Vitamin Solution 
(100×) was additionally added for boosting cell growth and viability.  Stable cells were 
collected from exponential phase and were resuspended in 0.36% (w/v) top agar.  Top and 
bottom agar contained the same components except for the percentage of agar.  Low-
melting top agar mix was then covered on the bottom agar.  Plates were overlaid with fresh 
agar every 7 days to maintain the nutrient elements.  Three parallel plates were set up for 
each cell line including the control.  Colonies were counted after a 3-week incubation.  
Colonies larger than ~0.1 mm in diameter were considered as positive.   
 
3.6 Kinome assay 
The kinome microarray was performed by Dr. Scott Napper’s lab.  The HEK 293 cells 
transfected with FRK-WT and untransfected HEK293 as control were both cultured to 
confluency in 10 cm culture plates respectively.  Cells were subsequently collected and 
lysed in 100 µL of prepared lysis buffer [Aprotinin (1 µg/ml), EDTA (1 mM), EGTA (1 
mM), NaCl (150 mM), NaF (1 mM), Na3VO4 (1 mM), leupeptin (1 µg/ml), PMSF (1 mM), 
Tris-HCl (pH 7.5, 20 mM), Triton (1%) and sodium pyrophosphate (2.5 mM)].  The lysates 
were then mixed with 70µL of an activation mix [ATP (50 µM), Brij-35 (0.05% v/v), BSA 
(0.25 mg/ml), 32P ATP (2 mCi/ml), Glycerol (50%), and MgCl2 (60 mM)] and applied to 
the microarrays.  These microarrays were incubated for 2 hours at 37°C and subsequently 
washed with 45mL of primary buffer [1% Triton X-100 in TBS buffer] and 45mL of 
secondary buffer [NaCl (2 M) and 1% Triton X-100 in TBS buffer].  Followed by air-
drying, the microarrays were exposed under the phosphorimager screen for 1 week.  Images 
were captured by using the TYPHOON® scanner (GE Healthcare) and processed by using 
the ImageQuant TL v2005 software.  Signal reproducibility was analysed by normalizing 
the acquired data and correcting for background noise.  The signal strength was calculated 
by using the GENESPRING® (Agilent Technologies) software.  
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3.7 Statistics 
Statistical analyses were conducted using SPSS 16.0 (SPSS, USA).  The normality of the 
data distribution was analyzed using Kolomogrov-Smirnov test.  The homogeneity of 
variance of samples was tested by Levene’s Test.  One-way Analysis of Variance 
(ANOVA) followed by a Tukey post-hoc analysis was used for data comparisons.  Data 
were represented by the mean ± S.D. (Standard Deviation) based on at least three 
independent experiments.  A p value of less than 0.05 was considered significant (*p < 
0.05, **p < 0.005). 
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4. RESULTS 
4.1 Expression of FRK in human breast cancer cell lines 
In the present study, using Western blots, the levels of FRK protein were determined in 
different breast cancer cell lines from various molecular subtypes including: HER2+ cells 
(AU565, SK-BR-3, HCC1419, HCC1569); ER+ cells (MDA-MB-361, MDA-MB-134-
VI); ER+/HER2+ cells (BT483, MCF7); triple negative cells (MDA-MB-231, HCC1395, 
BT549, MDA-MB-157, HCC1806), triple positive cells BT474 and normal immortalized 
mammary epithelial cell line MCF10A.  The relative levels of FRK was normalized to the 
expression of a house keeping gene, -tubulin and then normalized to MCF10A which is a 
non-cancer cell line.  The levels of FRK were found to be lowest in the triple negative cell 
lines MDA-MB-231 (0.31-fold) and HCC1395 (0.59-fold) compared to MCF10A (Figure 
4.1).  However, FRK was highest in the triple positive cell line BT474 (6.76-fold), triple 
negative cell line HCC1806 (6.61-fold), as well as ER/PR positive cell lines MCF7 (5.92-
fold) and BT483 (5.12-fold) compared to MCF10A (Figure 4.1).   
 Our goal was to also identify a breast cancer cell line with low or undetectable FRK 
levels that could be used to generate an FRK stable cell line.  Of the 13 cell lines examined, 
FRK was expressed lowest in the highly metastatic and tumorigenic cell line MDA-MB-
231.  These characteristics make MDA-MB-231 an ideal candidate for the stable 
expression of FRK for both in vitro and in vivo studies. 
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Figure 4.1.  Levels of FRK protein in various human cell lines.  (A) FRK is expressed 
in various human cell lines: triple positive (BT474), triple negative (MDA-MB-231, 
HCC1395, BT549, MDA-MB-157, and HCC1806), HER2 positive (AU565, SK-BR-3, 
HCC1419, and HCC1569), ER positive (MDA-MB-361, MDA-MB-134-VI), ER/PE 
positive (BT483, MCF7), normal immortalized mammary epithelial cell line MCF10A.  
(B) The FRK protein level in each cell line was normalized to its corresponding -tubulin 
control and then normalized to MCF10A.  The quantitative analysis was presented by the 
percentage of levels of FRK protein showing in the histogram.   
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4.2 Activity of GFP-FRK mutants 
In previous studies, mutations of murine FRK gene at 497 from tyrosine (Y) to 
phenylalanine (F) was shown to increase its kinase activity (Oberg-Welsh et al., 1998).  
Studies on BRK showed that GFP-BRK-Y447F is significantly more active than GFP-
BRK-WT, and that kinase-defective BRK (GFP-BRK-KM) has no enzymatic activity 
(Miah et al., 2012).  As shown in Figure 2.5, FRK has a functional architecture similar to 
that of BRK and Src family kinases.  Like Src kinases, BRK is negatively regulated by the 
phosphorylation of the C-terminal tyrosine 447, analogous to the regulatory Y530 of 
human Src and Y497 in human FRK (Derry et al., 2000; Qiu and Miller 2002).  The 
constitutive activation of the Src family of kinases is triggered by the mutation of the C-
terminal tyrosine to phenylalanine.  
In the present study, we aimed at determining the role of key conserved residue in 
human FRK activity.  We also examined whether reintroduction of the expression of FRK 
in MDA-MB-231 cell line that were devoid of endogenous FRK expression, could alter its 
phenotype and oncogenic properties.  Human FRK constructs: GFP-FRK wild-type (WT); 
kinase-defective GFP-FRK K262M (KM); GFP-FRK-C (lacking C-terminal amino acids 
497-505); and constitutive construct GFP-FRK-Y497F (Y497F) were generated and stably 
transfected in MDA-MB-231 cells.  All of the human FRK mutants were cloned as 
recombinant proteins in pEGFP expression vector as previously described (Section 3.3.1).   
As shown in Figure 4.2, using anti-phosphotyrosine antibody (pY20) to detect the 
level of tyrosine phosphorylation (a measure or indication of kinase activity) we observed 
that both GFP-FRK-Y497F (lane 2) and GFP-FRK-C (lane 1) displayed a significantly 
higher kinase activity as compared to GFP-FRK-WT (lane 3).  GFP-FRK-Y497F induced 
the phosphorylation of several potential substrates as compared to GFP-FRK-C (Figure 
4.2, upper panel).  The enhanced kinase activity of GFP-FRK-Y497F indicated that the 
C-terminal tyrosine 497 is essential for the regulation of FRK activity.  As expected, the 
kinase activity was significantly suppressed in the FRK-KM expressing cells compared to 
the control parental HEK 293 cells (lane 4 and 5 respective) (Figure 4.2).   
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Figure 4.2.  FRK-Y497F mutant is significantly more active than WT. HEK 293 cells 
were transfected with GFP-FRK constructs (WT, K262M, C (497-505), Y497F). Cell 
lysates were immunoblotted using anti-phosphotyrosine antibody pY20. GFP-FRK 
expressions were detected by anti-GFP antibodies (middle panel). The asterisks in lane 2 
(top panel) show the positions of potential FRK substrates. The arrow shows the potential 
auto-phosphorylation of FRK in lane 1, 2 and 3. Lane 4 contained GFP-FRK-K262M 
(kinase-dead) and reveals no tyrosine-phosphorylated substrates as expected.  The 
experiment was repeated at least three times and the figure was the representation of the 
average result.   
 
 
47 
 
4.3 Subcellular localization of FRK in human cells 
4.3.1 Subcellular localization of endogenous FRK in human breast cancer cells 
Human FRK has a nuclear localization signal (KRLDEGGFFLTRRR motif) embedded in 
the SH2 domain (Serfas and Tyner 2003).  Unlike the mouse FRK ortholog BSK/IYK, the 
human FRK lacks the myristoylated N-terminal consensus sequence (MGXXXS/T) that 
enables membrane anchorage (Serfas and Tyner 2003) (Figure 2.6).  We hypothesized that 
human FRK localizes in the nucleus; however, using immunofluorescence on FRK-
positive breast cancer cell lines AU565, SKBR3, MDA-MB-468, we observed that FRK 
was predominantly localized in the non-nucleus (Figure 4.3).  In order to validate the 
localization of endogenous FRK determined by immunofluorescence, subcellular 
fractionation followed by Western blotting using specific antibodies directed against FRK, 
Sam68 (a Src-Associated substrate in Mitosis of 68 kDa) and PTEN was performed on 
AU565 and SKBR3 (Table 4.4).  Sam68, a known nuclear RNA-binding protein served as 
a control for nuclear localization (Lukong and Richard 2007).  Endogenous FRK was 
detected mainly in the cytosolic fraction; however, low levels of FRK were observed in the 
isolated membrane fractions (Figure 4.4).   
 Based on the literature, FRK was shown to promote the stability of PTEN in MCF7 
cells (Yim et al., 2009).  We were also interested in the association between PTEN and 
FRK.  We used subcellular fractionation and western blots to analyze the protein level of 
PTEN to examine if the localization of PTEN correlated with that of FRK.  Interestingly, 
we found that the localization of PTEN did correlate with that of FRK since PTEN also 
localized predominantly in the cytosol and membrane fractions.   
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 Figure 4.3.  Endogenous FRK localizes in the cytoplasm in breast cancer cells.  The 
indicated breast cancer cells were seeded onto coverslips in 6-well cell culture plates and 
immunofluorescence was performed using rabbit anti-FRK antibodies (red).  The cells 
were also stained with DAPI to visualize the nucleus (blue). 
 
 
 
 
  
Figure 4.4.  Endogenous FRK predominantly localizes in the membrane in breast 
cancer cells.  Subcellular fractionation of breast cancer cells AU565 and SKBR3 was 
performed using the ProteoExtract Subcellular Proteosome Extraction Kit.  Cell lysates of 
the various fractions were immunoblotted with anti-FRK, anti-Sam68, anti-BRK and anti-
PTEN antibodies.  Sam68 is a nuclear protein and was used as a control for nuclear 
localization. 
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4.3.2 Subcellular localization of exogenous FRK in human cells 
In order to further substantiate the cytoplasmic or membrane cellular localization of FRK, 
HEK293 cells were transiently transfected with FRK (FRK-WT, FRK-KM, FRK-Y497F) 
using plasmid constructs that were tagged with GFP (to enable the evaluation of exogenous 
FRK).  On examination of the GFP immunofluorescence, all FRK plasmid constructs 
exhibited a non-nuclear staining, however, the distribution of FRK-Y497F was punctate-
like (Figure 4.5A).  To ensure that GFP had no effect on the localization of FRK, FRK 
plasmids lacking a GFP insert (LPC-FRK-WT and LPC-FRK-Y497F) were transiently 
transfected in HEK293 cells.  The LPC-FRK proteins encoded by the transiently 
transfected constructs displayed the same cytoplasmic localization pattern as seen with the 
FRK-GFP-tagged constructs (Figure 4.5B).  We therefore concluded that both 
endogenously and exogenously expressed FRK localize in the cytoplasm but not in the 
nucleus as we hypothesized.  Our previous hypothesis was based on the previously reported 
notion that FRK exerts a nuclear localization signal (Cance et al., 1994). 
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Figure 4.5.  Exogenously expressed FRK variants localize in the cytoplasm in HEK 
293 cells.  (A) HEK 293 cells were transfected with GFP-FRK constructs (WT, K262M, 
C (497-505), Y497F).  GFP expression was visualized by immunofluorescence 
microscopy.  The cells were also stained with DAPI to visualize the nucleus (blue).  (B) 
HEK 293 cells were transfected with LPC-FRK constructs (WT, Y497F).  FRK expression 
was reflected by using mouse anti-FRK antibody (red).  The nucleus localization was 
shown by DAPI staining (blue). 
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4.4 Characterization of the FRK-WT-MDA-MB-231 and FRK-Y497F-MDA-MB-231    
stable cell lines  
Plasmid constructs encoding either the FRK wild type (WT) or mutant (Y497F) protein 
were stably transfected into MDA-MB-231 breast cancer cells.  The MDA-MB-231 cell 
line was selected because they are highly tumorigenic and have low endogenous FRK 
expression levels (Section 4.1).  The colonies of the MDA-MB-231-FRK cell lines (WT-
1, 2 and 3; Y497F-1 and 2) that were selected for evaluation expressed higher levels of 
either the wild-type or mutant FRK protein compared to the endogenous levels in the 
parental MDA-MB-231 cells (Control).  Clones WT3 and YF1 were selected for use in the 
subsequent experiments and were referred to as FRK-WT and YF (Figure 4.6). 
 
 
 
Figure 4.6.  Both wild-type and constitutively active cell lines stably over-express 
FRK.  FRK-WT and FRK-Y497F were both generated in MDA-MB-231 cell line.  
Western blot analysis was used to validate the expression of FRK (FRK-WT and FRK-
Y497F).  Cell lysates of the selected stable cell lines were immunoblotted using anti-FRK 
antibody.  -Tubulin was served as a loading control.  Untransfected MDA-MB-231 cell 
line was used as control. 
 
 
4.5 Morphology of MDA-MB-231 FRK stable cells 
In a previous study, overexpression of FRK in the MCF7 breast cancer cells was reported 
to induce a cellular morphological change from a rounded to a stellate appearance (Yim et 
al., 2009).  In order to determine whether the introduction of FRK would affect MDA-MB-
231 cell morphology, we examined MDA-MB-231-FRK stable cells expressing either WT 
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or Y497F proteins for morphological differences.  Cells cultured in 10 cm culture dishes 
were photographed at 40× magnification.  The MDA-MB-231 cells that stably express 
either the WT or Y497F FRK proteins appeared to be more rounded compared to the 
stellate (spindle shaped) control cells (Figure 4.7).  Both MDA-MB-231 cells that express 
stable levels of either the FRK-WT or FRK-Y497F appeared larger in size as compared to 
the control parental MDA-MB-231 breast cancer cell lines (Figure 4.7). 
           
 
Figure 4.7.  Morphologic difference between FRK-overexpressing MDA-MB-231 
stable cells and control cells.  FRK-negative MDA-MB-231 cells were transfected with 
the retroviral viruses expressing FRK-WT and FRK-Y497F.  Cultures were photographed 
at inverted microscope with a 40X phase contrast objective. 
 
4.6 Effects of FRK on MDA-MB-231 cell properties 
FRK was previously reported as a candidate tumor suppressor gene in breast cancer (Yim 
et al., 2009).  Our goal was to evaluate the effects of FRK on the phenotypic characteristics 
of MDA-MB-231 breast cancer cells and also look at how constitutive activation of FRK 
induced by the mutation Y497F affected oncogenic processes such as cell proliferation, 
migration, invasion and colony formation.   
 
4.6.1 Proliferation of FRK expressing MDA-MB-231 cells 
The proliferation rate of the MDA-MB-231-FRK stable cell lines was measured using an 
MTT assay.  The MTT assays are a measure of the mitochondrial activity, which is a direct 
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reflection of the number of viable cells and cell vitality (metabolic activity).  Introduction 
of FRK (WT and Y497F) in MDA-MB-231 cells significantly diminished cell proliferation 
rate and metabolic activity as compared to the parental of MDA-MB-231 cells, 4 days after 
seeding the stable cell lines in a 96 wells plate (P < 0.005) (Figure 4.8).  After 4 days in 
culture, the fold increase in MDA-MB-231, MDA-MB-231-FRK-WT and MDA-MB-231-
Y497F was 11, 8, and 7-fold, respectively (4 days, P < 0.005).  FRK-Y497F had a greater 
suppressive effect on cell proliferation than FRK-WT (P < 0.005).   
 
Figure 4.8.  FRK-Y497F variant significantly decreases the proliferation of MDA-
MB-231 breast cancer cells compared FRK-WT.  An MTT assay was used to measure 
the proliferation rate of MDA-MB-231 cells that stably expressed either FRK-WT or FRK-
Y497F; controls were devoid of FRK expression.  Cell density at day 1, 2, 3, 4 after plating 
were measured by absorbance at 450 nm.  For each cell line, fold change in growth was 
calculated by normalization to the corresponding absorbance at day 0.  After 96 hours the 
cell proliferation was lower in cells that expressed FRK (WT or Y497F) as compared to 
the control cells.  Data are represented as the mean±S.D. and based on at least three 
independent experiments (n=6).  * P < 0.05, **P < 0.005. 
 
 
4.6.2 Migration of FRK expressing MDA-MB-231 cells 
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A wound-healing assay was used to investigate the migratory effects of MDA-MB-231.  
When the different MDA-MB-231 cell lines attained confluency, two scratches that run 
perpendicular to each other across the diameter of a 10 cm well plate were introduced.  As 
illustrated in Figure 4.9A, 36 hours after introduction of the perpendicular scratches in the 
confluent cells, the percentage of open area in the MDA-MB-231-FRK-WT and FRK-
Y497F plated cells dropped to 14%, and 30%, respectively; while, that of the parental 
MDA-MB-231 was 4%.  This implied that both MDA-MB-231-FRK stable cell lines had 
lower migration rates as compared to parental cell line (P < 0.05; Figure 4.9B, 4.9C).  To 
ensure the GFP has no effect on cell migration, a cell line stably expressing GFP alone was 
generated, and the wound-healing assay was conducted.  These was no difference in cell 
migration rates between the parental MDA-MB-231 cell line and the MDA-MB-231-GFP 
cell line (data not shown).  The significant difference between the rates of migration of 
FRK-WT (65% open area) and FRK-Y497F (68% open area) stable cell lines first appeared 
18 hours after wounding (P < 0.05; Figure 4.9B, 4.9C).  This difference then became 
apparent 36 hours after wound introduction (P < 0.005; Figure 4.9B, 4.9C).  We concluded 
that FRK-YF enhanced the suppression of cell migration compared to FRK-WT.  The 
migration was closely related to the cellular invasiveness; as such we evaluated the effect 
of FRK activity on the invasive property of MDA-MB-231 cell line. 
 
4.6.3 Invasiveness of FRK expressing MDA-MB-231 cells 
The invasive characteristics of MDA-MB-231 cell lines were investigated using a transwell 
system that was precoated with gelatin.  Three-dimensional gelatin was used as an 
intermediate for the invasion of the tumor cells from the surface to the inner gel.  The 
gelatin matrix assay provides an in vitro system that mimics the metastatic behavior of 
cancer cells in vivo.  Over expression of FRK- (WT and Y497F) in MDA-MB-231 
significantly repressed the number of cells that traversed the gelatin matrix as compared to 
parental MDA-MB-231 cells (P < 0.05; Figure 4.10).  The constitutively active FRK-
Y497F exerted a greater repression of the MDA-MB-231 invasiveness characteristics than 
the FRK-WT (P < 0.05; Figure 4.10).  Results from the invasion assay were in agreement 
with those of the proliferation and migration assay and further confirmed that the activity 
of FRK significantly repressed the invasive nature of MDA-MB-231 cells. 
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Figure 4.9.  Stable expression of FRK-Y497F and FRK-WT suppresses migration of 
MDA-MB-231 breast cancer cells.  (A) The migration of MDA-MB-231 cells that over-
expressed FRK-WT and FRK-Y497F was analyzed by using a wound-healing assay.  The 
percentage of wound showing at the bottom of each figure was measured by TScratch 
software.  (B) Cells that expressed FRK (WT and Y497F) had a significantly greater wound 
area than control from 24 to 36 hours. The average of three independently performed 
wound-healing assays is shown as a bar chart and a line chart.  Data are represented by the 
mean±S.D. and based on at least three independent experiments.  * P < 0.05, **P < 0.005. 
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Figure 4.10.  Over-expression of FRK-Y497F and FRK-WT significantly suppresses 
the invasive ability of MDA-MB-231 breast cancer cells.  (A) The invasive property of 
MDA-MB-231 cells that over-expressed either FRK-WT or FRK-Y497F was determined 
using a transwell assay.  Crystal violet staining was used to visualize the invasive cells.  
The number of cells that migrated across the transwell for each cell line that overexpressed 
either FRK-WT or FRK-Y497F was normalized to the controls (FRK negative).  Cell 
invasion was significantly suppressed by the over expression of FRK (WT or Y497F).  (B) 
The average of three independently performed transwell assays was shown as a bar chart.  
Data are represented by the mean±S.D. and based on three independent experiments per 
panel.  * P < 0.05, **P < 0.005. 
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4.6.4 Colony formation of FRK expressing MDA-MB-231 cells 
Anchorage-independent growth has been reported as one of the hallmarks of tumor cell 
transformation (Hanahan and Weinberg 2000).  The effect of FRK activity on the 
anchorage-independent growth was measured using a soft agar colony formation assay.  
Exogenous expression of FRK-WT and FRK-Y497F significantly repressed the MDA-
MB-231 cell growth in a soft agar gel as compared to that of the control parental MDA-
MB-231 cells (P < 0.005; Figure 4.11).  The suppressive function of FRK-Y497F (48 
cells/field) was higher than that of FRK-WT (P < 0.05; Figure 4.11).  Interestingly, the 
colony sizes of parental MDA-MB-231 cells was greater than that of both the MDA-MB-
231-FRK-WT and MDA-MB-231-FRK-Y497F cells (Figure 4.11).  We concluded that 
the introduction of FRK (WT and Y497F) repressed both cell proliferation and colony 
formation in the soft agar assays.  As well, the constitutively active form FRK-Y497F had 
a greater repressive effect than FRK-WT on colony formation, consistent with its effect on 
cell proliferation, migration and invasiveness as reported in the literature.  
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Figure 4.11.  FRK significantly suppresses the anchorage-independent growth of 
MDA-MB-231 breast cancer cells.  (A) A soft agar assay was conducted to investigate 
the role of FRK in the formation of cell colonies.  The expression of FRK in MDA-MB-
231 cells decreased the number of colonies formed after 21 days in that was evaluated in 
three randomly selected fields from each plate at magnification of 40X.		(B) The average 
of three independently performed soft agar assay was shown as a bar chart.  Data are 
represented by the mean±S.D. and based on three independent experiments per panel.  * 
P < 0.05, **P < 0.005.	
 
60 
 
4.7 Identification of FRK-regulated signaling pathways 
4.7.1 Kinome analysis 
We have shown that FRK indeed has tumor suppressor activity.  However, the growth 
inhibitory mechanism of action of FRK has not been fully defined.  The goal of this section 
of the project was to use kinome analysis to identify the signaling pathways regulated by 
FRK in order to understand the mechanism by which FRK exerts its tumor suppressive 
effect on breast cancer cells.  This part of the project was done in collaboration with Dr. 
Scott Napper (Vaccine and Infectious Disease Organization, University of Saskatchewan, 
Saskatoon, Canada).  Since FRK was reported to be expressed in certain non-cancer cell 
tissues (Chen et al., 2013), we are interested in the function of FRK in a non-cancer cell 
line.  Besides, HEK 293 is a well-studied cell line and easy to be transfected with.  
Therefore, we decided to use HEK 293 cells.  HEK 293 cells were transiently transfected 
with a plasmid that encoded the full length FRK wild-type protein (FRK-WT).  Cell lysates 
of transfected and untransfected HEK 293 cells were harvested and used in a kinome array 
assay (refer to Section 4.7).  An aliquot of the lysates was incubated on a kinome array 
composed of 300 peptides spotted in triplicates on slides.  The majority of the peptides on 
the array were derived from signaling intermediates of various signaling pathways 
including the MAPK and the JAK/STAT cascades (Figure 4.12).  Besides PTEN which is 
the only FRK substrate discovered so far, our data indicated that FRK can also potentially 
phosphorylate several cellular targets (Figure 4.2; Table 4.1).  Our kinome data showed 
that phosphorylation levels of proteins involved in the JAK-STAT pathway that included 
JAK1, BCL2, JNK1, STAT1 and STAT3, were significantly suppressed in the HEK-293 
cells transiently transfected with the FRK-WT full length protein as compared to the non-
transfected HEK 293 cells (Table 4.1).  This data was particularly interesting because it 
was previously shown that FRK inhibited JNK signaling in glioblastoma (Zhou et al., 
2012).  Since SAPK/JNK belongs to the MAPK signaling cascades, we are also interested 
in the effects on other cascades, such as p38 MAPK, ERK1/2 (Figure 2.1). 
 
4.7.2 Validation of Kinome data 
Using Western blot analysis, we evaluated signaling targets that were either significantly 
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phosphorylated or de-phosphorylated in the kinome assay following over-expression of 
FRK in HEK 293 cells (P < 0.05; Table 4.1).  Cell lysates of FRK-WT and FRK-Y497F 
that were harvested from the MDA-MB-231 stable cell lines and untransduced MDA-MB-
231 cells as control were immunoblotted with the antibodies against AKT, phospho-AKT, 
MEK 1/2, phospho-MEK 1/2, MAPK, phospho-MAPK, P38 MAPK, phospho-P38 
MAPK, JNK, phospho-JNK, STAT3, phospho-STAT3, FRK and -Tubulin as control.  
The exogenous expression of either the FRK-WT or the FRK-Y497F in the MDA-MB-231 
cells repressed the phosphorylation of several signaling intermediates including STAT3 to 
p-STAT3, JNK to p-JNK, p38 MAPK to pp38 MAPK, AKT to p-AKT and MEK 1/2 to p-
MEK 1/2 (P < 0.005; Figure 4.13).  Expression of the FRK-Y497F in MDA-MB-231 cells 
resulted in a greater repression of the phosphorylation of STAT3, JNK, p38 MAPK, AKT 
and MEK1/2 as compared to the FRK-WT (P < 0.05; Figure 4.13).  However, we observed 
a two fold increase in the activation of ERK1/2 following the introduction of FRK-WT and 
FRK-Y497F in MDA-MB-231 cells (P < 0.05; Figure 4.13).  ERK 1/2 phosphorylation 
level was greater in MDA-MB-231 cells that expressed FRK-Y497F as compared to cells 
that expressed FRK-WT (P < 0.005; Figure 4.13).  We concluded that the overexpression 
of either FRK-WT or Y497F repressed the phosphorylation of STAT3, JNK, AKT, p38 
MAPK and MEK 1/2; while it up-regulated the phosphorylation of ERK 1/2.   
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 Table 4.1.  Upregulated and downregulated proteins were detected by kinome array. 
The targets in red are intermediates in the JAK-STAT pathway.  FRK-WT was transiently 
transfected into HEK 293 cells. Untransfected HEK 293 cells were used as a control.  
p<0.05 was considered as significant. 
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Figure 4.12.  FRK suppresses the activation of STAT3.  (A) - (F) FRK-negative MDA-
MB-231 cells were transduced with the retroviral viruses expressing FRK-WT and FRK-
Y497F.  Lysates from FRK-WT and FRK-Y497F stable MDA-MB-231 cell lines and 
control cells were subjected to SDS-PAGE analysis followed by immunoblotting with 
antibodies against the indicated proteins. The over expression of FRK in MDA-MB-231 
cells decreased the phosphorylation of AKT, JNK, MEK1/2, P38 MAPK, STAT-3, and 
increased the phosphorylation of ERK1/2.  Quantification of western blot bands was 
analyzed by Image J software.  Two isoforms were given by one number since their 
tendency of change was the same.  Quantification of each pair of proteins is presented as a 
bar chart.  Data are represented by the mean±S.D. and based on at least three independent 
experiments. * P < 0.05, **P < 0.005. 
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5. DISCUSSION AND FUTURE DIRECTIONS 
5.1 Discussion and future direction 
5.1.1 The expression pattern of FRK in human breast cancer cell lines 
In the mammary gland and the human brain, FRK has been shown to be a tumor suppressor 
(Cance et al., 1994; Yim et al., 2009; Zhou et al., 2012); however, in the colon it promoted 
tumorigenesis (Cance et al., 1994).  In humans, FRK is prevalent in approximately 30% 
of the tumor samples collected from breast and colon (Cance et al., 1994).  It is 
predominantly expressed in epithelial cells but not the mesenchymal and hematopoetic 
cells (Cance et al., 1994).  However, the profile of FRK expression in breast cancer 
epithelial cell lines is unknown.  In a recent study the expression of FRK was linked to the 
severity of human brain cancer (Zhou et al., 2012).  In that study, it has been shown that 
the low expression level of FRK in glioblastomas was associated with aggressive tumors; 
while non-tumorous brain tissue had high FRK expression (Zhou et al., 2012).  A 
correlation between the expression level of FRK and the histological and molecular 
subtypes of breast cancer has not been yet examined or reported.  
In our study, we examined the expression patterns of FRK in a cohort of breast 
cancer cells derived from the mammary gland epithelium that were categorized into 5 
groups based on their molecular subtypes (ER+, ER/PR+, HER2+, triple negative and triple 
positive) (Rakha et al., 2010).  First, FRK was examined in 13 breast cancer cell lines; 
however, the expression was lowest in triple negative cell lines MDA-MB-231 and 
HCC1395 (Figure 4.1).  The MDA-MB-231 cell line is derived from the mammary gland 
epithelia and was isolated from pleural effusion (Brinkley et al., 1980).  Due to its 
oncogenic properties, rapid growth, metastasis and low endogenous expression of FRK, 
MDA-MB-231 was selected as a candidate for cellular assays used in this project.  Second, 
Iyk, the mouse FRK ortholog, has been suggested to differ in localization depending on the 
ratio of estrogen and progesterone levels (Berclaz et al., 2000).  We hypothesized that the 
expression of FRK might be correlated to these hormonal receptors as well.  In our data, 
the expression levels of FRK were high in cell lines (BT474, BT483 and MCF7) that 
expressed both the estrogen and progesterone receptors (ER/PR positive and triple 
positive); while, the levels were lower in cell lines that expressed either ER or HER2 alone 
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(AU565, SK-BR-3, HCC1419, HCC1569, MDA-MB-361 and MDA-MB-134-VI).  HER2 
has been reported to be overexpressed in more aggressive breast cancer cell lines (Sotiriou 
and Pusztai 2009).  FRK levels have also been shown to be low in high grade brain tumors 
(Zhou et al., 2012).  Compared to the HER2 negative groups (ER+ and ER/PR+), it is 
obvious that the average expression level of FRK was lower in HER2+ cell lines such as 
AU565, SK-BR-3 and HCC1569 (Figure 4.1), indicating the possible tumor-suppressive 
function of FRK which is consistent with the previous study.  Although the sample size of 
cell lines was small, our preliminary data still suggested the potential correlation between 
expression pattern of FRK and the presence of certain receptors in breast cancer cell lines.   
Recent data from Dr. Lukong’s lab obtained during the preparation of this thesis 
shows FRK expression in 77.5% of breast cancer cell lines tested (data not shown).  In the 
future study, larger sample size of cell lines and more categories of breast cancer cell lines 
will be used to acquire the complete FRK expression profile and the association between 
FRK expressing and molecular subtypes of breast cancer cell lines. 
 
5.1.2 The cytoplasmic localization of FRK in human breast cancer cell lines 
One of the goals of the present study was to examine the localization of FRK in FRK-
positive breast cancer cells.  We also examined the localization of exogenously expressed 
FRK wild-type and constitutively active variant FRK-Y497F.  In our study, using 
immunofluorescence and subcellular fractionation, endogenous FRK was mostly detected 
in the cytoplasm and/or cell membrane rather than in the nucleus in breast cancer cell lines 
SKBR3, MDA468 and AU565 (Figure 4.3; 4.4).  This is in contrast with Cance et al. and 
Meyer et al. studies on COS-7 monkey kidney cells and BT474 human breast cancer cells, 
where FRK was detected predominantly in the nucleus or perinucleus (Cance et al., 1994; 
Meyer et al., 2003).  It is worth noting that in the first study by Cance et al. the resolution 
of immunofluorescence data was not high and a control for nuclear staining was not shown.  
FRK has been reported to possess a putative bipartite nuclear localization signal motif 
buried in the SH2 domain (Chandrasekharan et al., 2002).  Glycine 2 in the myristoylation 
motif which is responsible for the anchorage of the protein to the plasma membrane is 
absent in human FRK (Chandrasekharan et al., 2002).  The known tumor suppressor PTEN, 
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which has been confirmed as one of substrates of FRK and to be stabilized by FRK, also 
localized in the cytoplasm instead of nucleus (Figure 4.4).  It is possible that FRK is 
sequestered to distinct cytoplasmic compartments by its interacting proteins that may 
explain why FRK and PTEN colocalize in the cytoplasm.  Exogenously expressed FRK 
displayed the same localization pattern as well (Figure 4.4).  It is worth mentioning that 
FRK has also been observed in the nucleus as well as in the cytoplasm in breast cancer cell 
line BT-20, supporting the possibility of various localization patterns across diverse cell 
lines (Cance et al., 1994).  Interestingly, we also found that the majority of FRK displayed 
a punctate localization pattern in the cytoplasm.  In a recent study FRK was shown to have 
a punctate cytoplasmic localization in human hepatocellular carcinoma cell line Hep3B 
(Pilati et al., 2014), and this data is consistent with our results.  However, the reason for 
the punctate cytoplasmic distribution is still unknown.   
The localization of the FRK mouse ortholog Iyk has been shown to depend on the 
hormonal status (Berclaz et al., 2000).  Another study on Bsk also reported that the tyrosine 
497 and 504 altered the localization of the protein (Oberg-Welsh et al., 1998).  Our other 
goal was therefore to examine whether the activity of FRK affects the subcellular 
localization of the protein.  Our data showed no difference in localization between wild 
type FRK and constitutively active mutant, suggesting that the enzymatic activity of FRK 
has no effect on protein localization (Figure 4.5).  
 How the localization of FRK affects its cellular function is still unknown.  Studies 
on BRK have indicated that membrane targeted BRK has oncogenic properties while 
nuclear targeted BRK displayed tumor suppressive function (Derry et al., 2003).  It will be 
interesting in the future to target FRK to different cellular compartments in FRK-negative 
cells and examine the effect on cellular processes such as cell proliferation, migration, 
invasion and colonization. 
 
5.1.3 The tumor suppressive role of FRK in human breast cancer 
FRK has been proposed to function as a tumor suppressor in breast cancer via stabilizing 
the known tumor suppressor PTEN (Yim et al., 2009), which triggered our interest to 
investigate how the constitutive enzymatic activity of FRK would affect its tumor 
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suppressive property.  In our study, a series of cellular experiments showed that compared 
to the control group, both wild type and the constitutively active FRK significantly 
suppressed cell proliferation, migration, invasion and cell formation (Figure 4.7-4.11).  
These in vitro data also showed that constitutively active FRK-Y497F inhibited cell growth 
much more effectively compared to wild-type.  Consistent with the role of FRK in 
inhibiting cell proliferation, the same trend was observed in cell migration, invasion and 
colony formation studies.  FRK has been shown to induce a cell growth suppression by 
arresting cells in G1 phase in the breast cancer cell line BT474 and MCF7, and human 
glioma cell lines U251 and U87 (Meyer et al., 2003; Hua et al., 2014).  Furthermore, in the 
U251 and U87 cell lines the authors also found that the G1 arrest was induced by the down-
regulation of cyclin D1 accumulation and the up-regulation of pRb activation, decreasing 
the release of E2F which is responsible for entry into the S phase (Hua et al., 2014).  Future 
experiments examining the effect of FRK variants on cell cycle progression are necessary.   
Interestingly, FRK has also been suggested to have oncogenic properties in a few 
studies.  The tumorigenesis of FRK was first raised in 2005.  FRK has been found to fuse 
to the ETS transcription factor ETV6, endowing the fused protein with oncogenic 
properties (Hosoya et al., 2005).  A recent study showed that endogenous FRK has been 
found expressed in normal lung tissue and liver tumor, suggesting that the cellular function 
of FRK could be organ-specific (Chen et al., 2013).  Interestingly, Chen et al. also found 
the increased cell growth and transformation promoted by FRK has only been found in the 
HCC cell line Hep3B, but not HepG2, indicating the oncogenic properties could depend 
on cellular context as well.  The following year, this oncogenic function of FRK in the 
human HCC cell line was confirmed in another published paper (Pilati et al., 2014).  This 
study also showed that FRK was able to induce the tumor growth in human HCC Hep3B 
cell line (Pilati et al., 2014), supporting the idea that the cellular function of FRK could be 
tissue-specific.  The Hep3B and HepG2 are both derived from human hepatocellular 
carcinoma.  A few speculations were made to address the varying oncogenic properties in 
these two cell lines upon FRK overexpression.  Hep3B is generally a more malignant cell 
line compared to HepG2 which could imply that the Hep3B cell line is more prone to 
displaying an oncogenic potential (Chen et al., 2013).  A second reasoning may be 
attributed to the presence of Rb and p53 which are known tumor suppressors.  These 
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proteins are not expressed in Hep3B but are expressed in HepG2 (Singer et al., 2007; Chen 
et al., 2013).  Thus, it is possible that the proliferation-inducing potential of FRK in HepG2 
could be suppressed by p53 and Rb.  Therefore, in order to investigate the tissue-specific 
role of FRK, cells derived from different organs may be evaluated for FRK-mediated 
tumor-suppressive or pro-oncogenic function.  Additionally, a correlation between the 
expression pattern of FRK and p53/pRb could be examined in these tissues/cells.   
In addition to the effects on the cellular function, a morphological change from 
rounded to stellate shape due to the presence of FRK has also been observed in the MCF7 
breast cancer cell line (Yim et al., 2009).  Parental MDA-MB-231 cells displayed a spindle-
shaped morphology (Kenny et al., 2007).  We found that MDA-MB-231 cells stably 
expressing FRK-WT and FRK-Y497F were more rounded in shape.  It is possible that this 
morphological change may reverse the epithelial-mesenchymal transition (EMT).  EMT is 
a characteristic of tumor invasiveness in which epithelial cells acquire fibroblast-like 
properties, exhibit reduced cell-cell contacts and increased motility.  EMT is essentially a 
tumor cell transformation from an epithelial to a mesenchymal-like condition in which a 
“cadherin switch” occurs (Steinestel et al., 2014).  This however has to be confirmed in 
future studies, by examining the expression of the mesenchymal markers such as N-
cadherin, vimentin, fibronectin as well as the expression levels of “EMT master genes” 
such as Snail, Slug and Twist family (Thiery et al., 2009; Wendt et al., 2014), and epithelial 
markers such as E-cadherin, claudin and occludin in the FRK stable cell lines (Thiery et 
al., 2009).  IL-6 stimulation has been reported to upregulate the expression levels of twist 
and snail, which are EMT-related gene targets in human breast, neck and head tumors 
(Sullivan et al., 2009; Yadav et al., 2011).  Furthermore, the IL-6-induced EMT has been 
found to be dependent on STAT3 through the JAK-STAT pathway (Yadav et al., 2011).  
Therefore, the IL-6→STAT3→twist signaling axis has been postulated in breast cancer 
(Wendt et al., 2014).  During the preparation of the present thesis, our lab confirmed that 
IL-6-induced STAT3 activation is repressed by FRK, suggesting that the FRK-induced 
suppression of tumor cell proliferation via the JAK-STAT pathway may be one of its 
mechanisms of action.  Thus, the IL-6→STAT3→twist/snail axis needs to be investigated 
in future studies, by examining the expression of Twist and Snail genes in the presence or 
absence of FRK.  
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5.1.4 The regulatory role of FRK in signaling transduction in human breast cancer 
A variety of important biological processes including cell proliferation, migration and 
invasion in breast cancer have been tightly controlled by certain signaling pathways, such 
as MAPK and JAK-STAT kinase cascades.  As one of the main pathways in the MAPK 
signaling transductions, nuclear signaling by JNKs have been involved in the regulation of 
cell death and differentiation (Chen 2012).   
PTEN, a known tumor suppressor, has been identified as a substrate of FRK 
recently (Yim et al., 2009).  However, other substrates of FRK and the role of FRK tumor 
suppressor function have not been fully understood.  One of the aims of my study was 
therefore to identify new FRK-regulated proteins using a Kinome assay. 
In our study, we observed that the activation levels of several signaling 
intermediates including AKT, JNK, MEK 1/2, p38 MAPK and STAT3 were decreased 
when either FRK-WT or FRK-Y497F were overexpressed, compared to those in the FRK 
negative group (Figure 4.13).  Our data suggested that FRK suppressed the cell growth 
potentially via the inhibition of MAPK, AKT and JAK/STAT signaling pathways.  
pSTAT3, a marker for activation of JAK/STAT signaling, was significantly repressed via 
JAK-STAT pathway.  We consistently observed that elevated FRK activity enhanced its 
anti-cancer property possibly via the down-regulation of certain signaling pathways.  
Intriguingly, phosphorylation of ERK 1/2, a downstream target of MEK 1/2, was decreased 
in the presence of FRK-WT and FRK-Y497F.  It is important to note that a similar 
observation was reported in a previous study in which murine FRK-transgenic mice 
demonstrated higher phosphorylation level of ERK 1/2 but lower level of phosphorylated 
p38 in islet cells compared to control islets (Anneren and Welsh 2001).  This is in 
contradiction with the growth promoting role of pERK 1/2 (Cheng et al., 2013).  ERK 1/2 
has also been shown to negatively regulate the activation of STAT3 in human hepatoma 
cell line HepG2 (Tian and An 2004).  In that study, the suppression of pERK 1/2 allowed 
the increase of the phosphorylation level of STAT3 via serine 727 (Tian and An 2004).  In 
the same cell line, serine 727 has also been reported to reduce the activity of STAT3 via 
dephosphorylating the tyrosine 705 of STAT3 (Wakahara et al., 2012).  Based on these 
findings, we hypothesized that FRK may play an important role in regulating the signaling 
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pathways through the repression of the activity of JNK, p38, AKT and STAT3 respectively, 
as well as through a bypass mechanism that promotes ERK 1/2 activation and consequently 
suppresses phospho-STAT3 (Tian and An 2004) (Figure 5.1).  This may explain why the 
phosphorylation levels of STAT3 in FRK-WT (0.20-fold, p < 0.005) and FRK-Y497F 
(0.04-fold, p < 0.005) are both significantly less compared to the FRK negative control.   
It is worth mentioning that although the activity of MEK 1/2 decreased, an 
unexpected increase in the phosphorylation level has been observed in one of its 
downstream substrates, ERK 1/2, suggesting that besides MEK 1/2, ERK 1/2 may be 
regulated by multiple upstream kinases simultaneously (Figure 5.1).  It has been 
previously reported that ERK 1/2 can be upregulated by MEK 1/2, but downregulated by 
MEKK1 and p38 MAPK in neural systems (Lu and Xu 2006), indicating the decrease in 
the activity of p38 MAPK and other potential regulators could affect the phosphorylation 
level of ERK 1/2.   
Focal adhesion and integrin clustering have also been demonstrated to induce 
certain regulatory signaling pathways including cell migration, survival and differentiation 
(Hynes 2002; Mitra et al., 2005).  Focal adhesion kinase (FAK) has been known to 
participate in the integrin-associated signaling.  The activation of FAK at tyrosine 397 
provides the docking site for Src, CSK, GRB7, SOCS and PI3K (Mitra et al., 2005).  A 
subsequent Src-induced tyrosine phosphorylation of FAK at Y925 creates a binding site 
for GRB2, linking the integrins to the MAPK signaling (Mitra et al., 2005).  It will be 
interesting to examine whether the integrin-signaling and activity of FAK are affected by 
the presence of FRK. 
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Figure 5.1.  FRK inhibits the MAPK and JAK-STAT signaling pathway.  Cytokine 
receptor stimulation results in the phosphorylation of STAT3 at tyrosine 705, which 
induces dimerization, followed by nuclear translocation and activation of specific target 
genes containing the ISRE (IFN-stimulated Response Element).  Many STAT3 target 
genes are key components of the regulation of cell cycle progression from G1 to S phase.  
Other pathways such as MAPK (Mitogen Activated Protein Kinase), p38 MAPK, and 
MEK (MAPK/ERK Kinase) signaling cascades also lead to phosphorylation and activation 
of STAT3.  We have shown here that FRK strongly inhibits activation of MAPKs (JNK 
and p38) and STAT3, but promotes activation of ERK 1/2.  Figure is modified from 
http://www.sabiosciences.com/pathway.php?sn=STAT3_Pathway. 
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5.2 Conclusion and perspectives 
FRK is a candidate tumor suppressor whose expression and localization pattern as well as 
its mechanisms of action in mammary epithelial cancer cells have not been fully 
understood.  The present study was aimed at determining the expression and localization 
of FRK in breast cancer cells as well as the effects of stable overexpression of FRK on 
breast cancer cell proliferation, migration, invasion and colonization.  We also aimed at 
identifying FRK-modulated signaling pathways via kinome analysis.  A few significant 
conclusions can be draw from our data.  First, both endogenous and exogenous FRK 
localize mainly in the cytoplasm although FRK has been reported as a nuclear tyrosine 
kinase in other studies.  However, it is possible the subcellular localization may vary in 
different cell lines and FRK may be either an oncogene or tumor suppressor depending on 
tissue context.  Second, compared to wild-type FRK, the constitutively active variant FRK-
Y497F significantly enhances its tumor suppressive activity as determined by suppressed 
proliferation, migration, invasion, and transformation of MDA-MB-231 breast cancer cell 
line.  Third, FRK may inhibit these biological processes via the regulation of several 
signaling intermediates including MEK 1/2, ERK 1/2, AKT, p38 MAPK, JNK, and STAT3.  
Finally, the JAK-STAT3 signaling, an important signaling pathway known to regulate cell 
proliferation, is significantly inhibited by the presence of FRK.  Both Ras-Rac and Ras-
Raf1 induced MAPK signaling pathways are affected by the activation of FRK as 
determined by its inhibition of the activation of their corresponding signaling 
intermediates.  From our data we conclude that targeted over-expression of FRK could be 
a viable therapeutic strategy in breast cancer. 
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